

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents
United States Patent and Trademark
Office
Box PCT
Washington, D.C.20231
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 21 August 2000 (21.08.00)	
International application No. PCT/EP99/10176	Applicant's or agent's file reference JAB 1442-PCT
International filing date (day/month/year) 15 December 1999 (15.12.99)	Priority date (day/month/year) 19 December 1998 (19.12.98)
Applicant JANSSENS, Frans, Eduard et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:
20 May 2000 (20.05.00)

☐ in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was
☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

Best Available Copy

<p>The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland</p> <p>Facsimile No.: (41-22) 740.14.35</p>	<p>Authorized officer S. Mafla</p> <p>Telephone No.: (41-22) 338.83.38</p>
--	--


THIS PAGE BLANK (USPTO)



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷: C07D 471/20, A61K 31/55, 31/438, A61P 37/00, C07D 495/22, 487/20, 498/20, 519/00 // (C07D 471/20, 235:00, 223:00, 221:00) (C07D 495/22, 333:00, 235:00, 223:00, 221:00)	A1	(11) International Publication Number: WO 00/37470 (43) International Publication Date: 29 June 2000 (29.06.00)
(21) International Application Number: PCT/EP99/10176 (22) International Filing Date: 15 December 1999 (15.12.99) (30) Priority Data: 98204347.3 19 December 1998 (19.12.98) EP (71) Applicant (for all designated States except US): JANSSEN PHARMACEUTICA N.V. [BE/BE]; Patent Department, Turnhoutseweg 30, B-2340 Beerse (BE). (72) Inventors; and (75) Inventors/Applicants (for US only): JANSSENS, Frans, Ed- uard [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). LEENAERTS, Joseph, Elisabeth [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). (74) Agent: QUAGHEBEUR, Luc; Janssen Pharmaceutica N.V., Patent Department - ext 3547, Turnhoutseweg 30, B-2340 Beerse (BE).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>

(54) Title: ANTIHISTAMINIC SPIRO COMPOUNDS



(57) Abstract

This invention concerns the compounds of formula (I) a prodrug, a *N*-oxide, an addition salt, a quaternary amine or a stereochemically isomeric form thereof wherein R^1 is hydrogen, C_{1-6} alkyl, halo, formyl, carboxyl, C_{1-6} alkyloxycarbonyl, C_{1-6} alkylcarbonyl, $N(R^3R^4)C(=O)-$, $N(R^3R^4)C(=O)N(R^5)-$, ethenyl substituted with carboxyl or C_{1-6} alkyloxycarbonyl, or C_{1-6} alkyl substituted with hydroxy, carboxyl, C_{1-6} alkyloxy, C_{1-6} alkyloxycarbonyl, $N(R^3R^4)C(=O)-$, C_{1-6} alkyl $C(=O)N(R^5)-$, C_{1-6} alkyl $S(=O)_2N(R^5)-$ or $N(R^3R^4)C(=O)N(R^5)-$ wherein each R^3 and each R^4 independently are hydrogen or C_{1-6} alkyl, and R^5 is hydrogen or hydroxy; R^2 is hydrogen, C_{1-6} alkyl, hydroxy C_{1-6} alkyl, C_{1-6} alkyloxy C_{1-6} alkyl, $N(R^3R^4)C(=O)-$, aryl or halo; n is 1 or 2; $-A-B-$ represents a bivalent radical of formula $-Y-CH=CH-$, $-CH=CH-Y-$, or $-CH=CH-CH=CH-$, wherein each hydrogen atom may independently be replaced by R^6 wherein R^6 is C_{1-6} alkyl, halo, hydroxy, C_{1-6} alkyloxy, ethenyl substituted with carboxyl or C_{1-6} alkyloxycarbonyl, hydroxy C_{1-6} alkyl, formyl, carboxyl or hydroxycarbonyl C_{1-6} alkyl, and each Y independently is a bivalent radical of formula $-O-$, $-S-$ or $-NR^7-$, wherein R^7 is hydrogen, C_{1-6} alkyl or C_{1-6} alkylcarbonyl; Z is a bivalent radical of formula $-(CH_2)_p-$, $-CH=CH-$, $-CH_2-CHOH-$, $-CH_2-O-$, $-CH_2-C(=O)-$, or $-CH_2-C(=NOH)-$, provided that the bivalent radicals are connected to the nitrogen of the imidazole ring via their $-CH_2-$ moiety; and wherein p is 1, 2, 3 or 4; L is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl; C_{1-6} alkylcarbonyl; C_{1-6} alkyloxycarbonyl; C_{1-6} alkyl substituted with hydroxy, carboxyl, C_{1-6} alkyloxy, C_{1-6} alkyloxycarbonyl, aryl, aryloxy, cyano or R^8HN- wherein R^8 is hydrogen, C_{1-6} alkyl, C_{1-6} alkyloxycarbonyl, C_{1-6} alkylcarbonyl; or L represents a radical of formula $-Alk-Y-Het^1$, $-Alk-NH-CO-Het^2$ or $-Alk-Het^3$ wherein Alk represents C_{1-6} alkanediyl; Y represents O, S or NH; Het^1 , Het^2 and Het^3 each represent an optionally substituted heterocycle; for use as a medicine.

THIS PAGE BLANK (USPTO)

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakistan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		


THIS PAGE BLANK (USPTO)



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁷ : C07D 471/20, A61K 31/55, 31/438, A61P 37/00, C07D 495/22, 487/20, 498/20, 519/00 // (C07D 471/20, 235:00, 223:00, 221:00) <i>(Continued on the following page)</i></p>	A1	<p>(11) International Publication Number: WO 00/37470</p> <p>(43) International Publication Date: 29 June 2000 (29.06.00)</p>
<p>(21) International Application Number: PCT/EP99/10176</p> <p>(22) International Filing Date: 15 December 1999 (15.12.99)</p> <p>(30) Priority Data: 98204347.3 19 December 1998 (19.12.98) EP</p> <p>(71) Applicant (for all designated States except US): JANSSEN PHARMACEUTICA N.V. [BE/BE]; Patent Department, Turnhoutseweg 30, B-2340 Beerse (BE).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): JANSSENS, Frans, Eduard [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). LEENAERTS, Joseph, Elisabeth [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE).</p> <p>(74) Agent: QUAGHEBEUR, Luc; Janssen Pharmaceutica N.V., Patent Department - ext 3547, Turnhoutseweg 30, B-2340 Beerse (BE).</p>	<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	

(54) Title: ANTIHISTAMINIC SPIRO COMPOUNDS



(57) Abstract

This invention concerns the compounds of formula (I) a prodrug, a *N*-oxide, an addition salt, a quaternary amine or a stereochemically isomeric form thereof wherein R^1 is hydrogen, C_{1-6} alkyl, halo, formyl, carboxyl, C_{1-6} alkyloxycarbonyl, C_{1-6} alkylcarbonyl, $N(R^3R^4)C(=O)-$, $N(R^3R^4)C(=O)N(R^5)-$, ethenyl substituted with carboxyl or C_{1-6} alkyloxycarbonyl, or C_{1-6} alkyl substituted with hydroxy, carboxyl, C_{1-6} alkyloxy, C_{1-6} alkyloxycarbonyl, $N(R^3R^4)C(=O)-$, $C_{1-6}alkylC(=O)N(R^5)-$, $C_{1-6}alkylS(=O)_2N(R^5)-$ or $N(R^3R^4)C(=O)N(R^5)-$, wherein each R^3 and each R^4 independently are hydrogen or C_{1-6} alkyl, and R^5 is hydrogen or hydroxy; R^2 is hydrogen, C_{1-6} alkyl, hydroxy, C_{1-6} alkyloxy, $C_{1-6}alkyloxyC_{1-6}alkyl$, $N(R^3R^4)C(=O)-$, aryl or halo; n is 1 or 2; $-A-B-$ represents a bivalent radical of formula $-Y-CH=CH-$, $-CH=CH-Y-$, or $-CH=CH-CH=CH-$, wherein each hydrogen atom may independently be replaced by R^6 wherein R^6 is C_{1-6} alkyl, halo, hydroxy, C_{1-6} alkyloxy, ethenyl substituted with carboxyl or C_{1-6} alkyloxycarbonyl, hydroxy, C_{1-6} alkyl, formyl, carboxyl or hydroxycarbonyl, $C_{1-6}alkyl$, and each Y independently is a bivalent radical of formula $-(CH_2)_p-$, $-CH=CH-$, $-CH_2-CHOH-$, $-CH_2-O-$, $-CH_2-C(=O)-$, or $-CH_2-C(=NOH)-$, provided that the bivalent radicals are connected to the nitrogen of the imidazole ring via their $-CH_2-$ moiety; and wherein p is 1, 2, 3 or 4; L is hydrogen, C_{1-6} alkyl; C_2-6 alkenyl; C_{1-6} alkylcarbonyl; C_{1-6} alkyloxycarbonyl; C_{1-6} alkyl substituted with hydroxy, carboxyl, C_{1-6} alkyloxy, $C_{1-6}alkyloxycarbonyl$, aryl, aryloxy, cyano or R^8HN- wherein R^8 is hydrogen, C_{1-6} alkyl, $C_{1-6}alkyloxycarbonyl$, $C_{1-6}alkylcarbonyl$; or L represents a radical of formula $-Alk-Y-Het^1$, $-Alk-NH-CO-Het^2$ or $-Alk-Het^3$ wherein Alk represents C_{1-6} alkanediyl; Y represents O, S or NH; Het^1 , Het^2 and Het^3 each represent an optionally substituted heterocycle; for use as a medicine.

THIS PAGE BLANK (USPTO)

(Continued)

(C07D 495/22, 333:00, 235:00, 223:00, 221:00) (C07D 495/22, 235:00, 223:00, 221:00, 209:00) (C07D 487/20, 235:00, 223:00, 223:00) (C07D 471/20, 235:00, 221:00, 221:00)

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Kazakhstan	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LJ	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

THIS PAGE BLANK (USPTO)

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference JAB 1442-PCT	FOR FURTHER ACTION <small>see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.</small>	
International application No. PCT/EP 99/ 10176	International filing date (day/month/year) 15/12/1999	(Earliest) Priority Date (day/month/year) 19/12/1998
Applicant JANSSEN PHARMACEUTICA N.V. et al.		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 3 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

a. With regard to the language, the International search was carried out on the basis of the International application in the language in which it was filed, unless otherwise indicated under this item.

☐ the International search was carried out on the basis of a translation of the International application furnished to this Authority (Rule 23.1(b)).

b. With regard to any nucleotide and/or amino acid sequence disclosed in the International application, the International search was carried out on the basis of the sequence listing:

☐ contained in the International application in written form.

☐ filed together with the International application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the International application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

2. ☐ Certain claims were found unsearchable (See Box I).

3. ☐ Unity of invention is lacking (see Box II).

4. With regard to the title,

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the abstract,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this International search report, submit comments to this Authority.

6. The figure of the drawings to be published with the abstract is Figure No. _____

☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☐ None of the figures.

THIS PAGE BLANK (USPTO)

INTERNATIONAL SEARCH REPORT

International Application No

EP 99/10176

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D471/20 A61K31/55 A61K31/438 A61P37/00 C07D495/22
 C07D487/20 C07D498/20 C07D519/00 //(C07D471/20, 235:00,
 223:00, 221:00), (C07D495/22, 333:00, 235:00, 223:00, 221:00),

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 97 24356 A (JANSSEN PHARMACEUTICA NV ;) 10 July 1997 (1997-07-10) cited in the application page 14, line 25 - line 29; claims 1,8	1,10
A	EP 0 518 434 A (JANSSEN PHARMACEUTICA NV) 16 December 1992 (1992-12-16) page 27, line 7 - line 13; claims 1,7	1,10
A	EP 0 393 738 A (JANSSEN PHARMACEUTICA NV) 24 October 1990 (1990-10-24) page 15, line 15 - line 23; claim 1	1,10

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

30 March 2000

Date of mailing of the international search report

17/04/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5618 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Alfaro Faus, I

THIS PAGE BLANK (USPTO)

INTERNATIONAL SEARCH REPORT

International Application No

P 99/10176

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 (C07D495/22, 235:00, 223:00, 221:00, 209:00), (C07D487/20, 235:00, 223:00, 223:00), (C07D471/20, 235:00, 221:00, 221:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.

☐

Further documents are listed in the continuation of box C.

☒

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

30 March 2000

Date of mailing of the international search report

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Alfaro Faus, I

THIS PAGE BLANK (USPTO)

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

EP 99/10176

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
W0 9724356	A	10-07-1997	AU 716071 B	17-02-2000
			AU 1308697 A	28-07-1997
			BR 9612307 A	13-07-1999
			CA 2238817 A	10-07-1997
			CZ 9801865 A	11-11-1998
			EP 0843679 A	27-05-1998
			NO 982405 A	19-08-1998
			NZ 325845 A	29-06-1999
			PL 327136 A	23-11-1998
			SK 83098 A	11-01-1999
EP 0518434	A	16-12-1992	AU 652841 B	08-09-1994
			AU 1901192 A	12-01-1993
			CA 2102889 A	14-12-1992
			CN 1068116 A, B	20-01-1993
			WO 9222553 A	23-12-1992
			EP 0588859 A	30-03-1994
			FI 935557 A	10-12-1993
			HR 920156 A	31-12-1995
			HU 70428 A	30-10-1995
			IL 101851 A	14-05-1996
			JP 6507890 T	08-09-1994
			MX 9202860 A	01-12-1992
			NO 934493 A	04-01-1994
			NZ 242775 A	28-03-1995
			PL 170376 B	31-12-1996
			US 5461050 A	24-10-1995
			ZA 9204327 A	13-12-1993
			ZM 2892 A	25-05-1994
EP 0393738	A	24-10-1990	AT 114653 T	15-12-1994
			AU 615612 B	03-10-1991
			AU 5295190 A	11-10-1990
			CA 2013892 A	07-10-1990
			CN 1046161 A, B	17-10-1990
			DE 69014385 D	12-01-1995
			DE 69014385 T	20-04-1995
			DK 393738 T	16-01-1995
			ES 2067645 T	01-04-1995
			FI 95702 B	30-11-1995
			GR 3015154 T	31-05-1995
			HU 58324 A	28-02-1992
			IE 65460 B	01-11-1995
			IL 94008 A	18-02-1997
			JP 2290874 A	30-11-1990
			NO 174851 B	11-04-1994
			NZ 233088 A	25-10-1991
			PT 93671 A, B	20-11-1990
			RU 2030415 C	10-03-1995
			US 5272150 A	21-12-1993
			ZA 9002664 A	24-12-1991

THIS PAGE BLANK (USPTO)

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/10176

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D471/20 A61K31/55 A61K31/438 A61P37/00 C07D495/22
C07D487/20 C07D498/20 C07D519/00 //(C07D471/20, 235:00,
223:00, 221:00), (C07D495/22, 333:00, 235:00, 223:00, 221:00),

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 97 24356 A (JANSSEN PHARMACEUTICA NV ;) 10 July 1997 (1997-07-10) cited in the application page 14, line 25 - line 29; claims 1,8 ---	1,10
A	EP 0 518 434 A (JANSSEN PHARMACEUTICA NV) 16 December 1992 (1992-12-16) page 27, line 7 - line 13; claims 1,7 ---	1,10
A	EP 0 393 738 A (JANSSEN PHARMACEUTICA NV) 24 October 1990 (1990-10-24) page 15, line 15 - line 23; claim 1 -----	1,10

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

30 March 2000

Date of mailing of the international search report

17/04/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Alfaro Faus, I

THIS PAGE BLANK (USPTO)

INTERNATIONAL SEARCH REPORT

Inte. onal Application No

PCT/EP 99/10176

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 (C07D495/22, 235:00, 223:00, 221:00, 209:00), (C07D487/20, 235:00, 223:00, 223:00), (C07D471/20, 235:00, 221:00, 221:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.

☐

Further documents are listed in the continuation of box C.

☒

Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

30 March 2000

Date of mailing of the international search report

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Alfaro Faus, I

THIS PAGE BLANK (USPTO)

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inte: .onal Application No

PCT/EP 99/10176

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9724356	A	10-07-1997	AU 716071 B	17-02-2000
			AU 1308697 A	28-07-1997
			BR 9612307 A	13-07-1999
			CA 2238817 A	10-07-1997
			CZ 9801865 A	11-11-1998
			EP 0843679 A	27-05-1998
			NO 982405 A	19-08-1998
			NZ 325845 A	29-06-1999
			PL 327136 A	23-11-1998
			SK 83098 A	11-01-1999
EP 0518434	A	16-12-1992	AU 652841 B	08-09-1994
			AU 1901192 A	12-01-1993
			CA 2102889 A	14-12-1992
			CN 1068116 A,B	20-01-1993
			WO 9222553 A	23-12-1992
			EP 0588859 A	30-03-1994
			FI 935557 A	10-12-1993
			HR 920156 A	31-12-1995
			HU 70428 A	30-10-1995
			IL 101851 A	14-05-1996
			JP 6507890 T	08-09-1994
			MX 9202860 A	01-12-1992
			NO 934493 A	04-01-1994
			NZ 242775 A	28-03-1995
			PL 170376 B	31-12-1996
			US 5461050 A	24-10-1995
			ZA 9204327 A	13-12-1993
			ZM 2892 A	25-05-1994
EP 0393738	A	24-10-1990	AT 114653 T	15-12-1994
			AU 615612 B	03-10-1991
			AU 5295190 A	11-10-1990
			CA 2013892 A	07-10-1990
			CN 1046161 A,B	17-10-1990
			DE 69014385 D	12-01-1995
			DE 69014385 T	20-04-1995
			DK 393738 T	16-01-1995
			ES 2067645 T	01-04-1995
			FI 95702 B	30-11-1995
			GR 3015154 T	31-05-1995
			HU 58324 A	28-02-1992
			IE 65460 B	01-11-1995
			IL 94008 A	18-02-1997
			JP 2290874 A	30-11-1990
			NO 174851 B	11-04-1994
			NZ 233088 A	25-10-1991
			PT 93671 A,B	20-11-1990
			RU 2030415 C	10-03-1995
			US 5272150 A	21-12-1993
			ZA 9002664 A	24-12-1991

THIS PAGE BLANK (USPTO)

- 1 DEC 2000

From the
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

Patent department

To:

QUAGHEBEUR, Luc
JANSSEN PHARMACEUTICA N.V.
Patent Department - EXT. 3547
Turnhoutseweg 30
B-2340 Beerse
BELGIQUE

PCT

NOTIFICATION OF TRANSMITTAL OF
THE INTERNATIONAL PRELIMINARY
EXAMINATION REPORT

(PCT Rule 71.1)

Date of mailing
(day/month/year) 29.11.2000

Applicant's or agent's file reference
JAB 1442-PCT

IMPORTANT NOTIFICATION

International application No.
PCT/EP99/10176

International filing date (day/month/year)
15/12/1999

Priority date (day/month/year)
19/12/1998

Applicant

JANSSEN PHARMACEUTICA N.V. et al.

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/



European Patent Office
D-80298 Munich
Tel. +49 89 2399 - 0 Tx: 523656 epmu d
Fax: +49 89 2399 - 4465

Authorized officer

Exner, K

Tel.+49 89 2399-7826



THIS PAGE BLANK (USPTO)

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference JAB 1442-PCT		FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/EP99/10176	International filing date (day/month/year) 15/12/1999	Priority date (day/month/year) 19/12/1998	
International Patent Classification (IPC) or national classification and IPC C07D471/20			
Applicant JANSSEN PHARMACEUTICA N.V. et al.			

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.



2. This REPORT consists of a total of 7 sheets, including this cover sheet.

- ☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☒ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand 20/05/2000	Date of completion of this report 29.11.2000
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer Stroeter, T Telephone No. +49 89 2399 8088 

THIS PAGE BLANK (USPTO)

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/EP99/10176

I. Basis of the report

1. This report has been drawn on the basis of *(substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments (Rules 70.16 and 70.17).)*:

Description, pages:

1-53 as originally filed

Claims, No.:

1-15 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

THIS PAGE BLANK (USPTO)

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/EP99/10176

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims	3, 8, 10-13, 15
	No:	Claims	1, 2, 4-7, 9, 14
Inventive step (IS)	Yes:	Claims	3, 8, 10-13, 15
	No:	Claims	
Industrial applicability (IA)	Yes:	Claims	1-15
	No:	Claims	

2. Citations and explanations
see separate sheet

VII. Certain defects in the international application

The following defects in the form or contents of the international application have been noted:
see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:
see separate sheet

THIS PAGE BLANK (USPTO)

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/EP99/10176

Re Item V

Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1 Subject-matter of the independent claims

The present application refers to 4-(imidazoazepine)piperidine spiro derivatives (independent claims 1, 9 and 12), their preparation (independent claims 14 and 15), pharmaceutical compositions (independent claim 10) comprising such compounds and the preparation of such compositions (independent claim 11) .

2 Prior art documents

Reference is made to the following documents. The given numbering will be adhered to in the rest of the procedure:

D1: WO 97 24356 A (JANSSEN PHARMACEUTICA NV ;) 10 July 1997 (1997-07-10), cited in the application

D2: EP-A-0 518 434 (JANSSEN PHARMACEUTICA NV) 16 December 1992 (1992-12-16)

D3: EP-A-0 393 738 (JANSSEN PHARMACEUTICA NV) 24 October 1990 (1990-10-24)

3 Novelty (Article 33(2) PCT)

D2 and D3 disclose related compounds having antihistaminic activity but without a spiro moiety and are therefore not relevant to the question of novelty.

D1, however, mentions on page 12, first reaction scheme, a group of compounds of formula (III), in particular formula (III-a-2-1), which overlap with the compounds as claimed in present **claim 1** if present L = H and n = 1 with present A-B, Z (corresponds to Z resp. Z¹ of D1), R¹ (corresponds to R⁴ of D1) and R² (corresponds to R⁵ of D1) having partially similar specifications.

THIS PAGE BLANK (USPTO)

Therefore D1 takes away the novelty of present claim 1 and of dependent **claims 2, 4 to 7** and independent **claims 9 and 14** by consequence.

Claims 3, 12 and consequently, 13 and 15 are novel due to the exclusion of the case $L = H$. Present **claim 8** names specific compounds not comprised in the group of compounds of formula (III-a-2-1) and is novel, too.

Present **claims 10 and 11** which are directed to pharmaceutical compositions and their preparation are novel, because the compounds have so far not been used as ingredients in such compositions.

At present it must be stated that the present application does not fulfil the requirements of Article 33(2) PCT.

4 Inventive step (Article 33(3) PCT)

On condition that the present set of claims is harmonized with Article 33(2) PCT by the Applicant, subject-matter of said claims can be at present regarded as inventive in view of D1, D2 and D3, because by revealing compounds of formula (I), the present application gives a non-obvious solution to the problem of how to provide further antihistaminic compounds.

D1 reveals the structurally closest compounds, but no antihistaminic activity is described for said compounds. Therefore D2 (or alternatively D3) is to be seen as closest prior art document. The presence of the parental system containing the spiro configuration is regarded as a major structural difference to the compounds of document D2 (resp. D3) and therefore it could not be foreseen by the skilled man that the presently claimed compounds would be active as described and therefore, the claims in question are to be seen as involving an inventive step according to Article 33(3) PCT.

THIS PAGE BLANK (USPTO)

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/EP99/10176

5 Industrial applicability (Article 33(4) PCT)

The subject-matter of the present set of claims 1 to 15 is in accordance with the requirements of Article 33(4) PCT.

Re Item VII

Certain defects in the international application

- (1) To meet the requirements of Rule 5.1(a)(ii) PCT, the documents D2 and D3 should have been identified in the description and the relevant background art disclosed therein should have been briefly discussed.
- (2) When entering the regional phase at the EPO, the expression "hereby incorporated" (page 3, line 20) should be deleted with respect to the EPC-Guidelines C-II, 4.18/ C-III, 4.3a.

Re Item VIII

Certain observations on the international application

Concerning clarity of the claims (Article 6 PCT) as filed by the Applicant, her attention is drawn to the following objections:

- (1) The functional term "prodrug" in **claims 1 and 8** leaves the reader in doubt about the structural feature to which said term refers and causes lack of clarity (Article 6 PCT) in said claim. Therefore this term has to be excelled from those claims and from the present description whenever it appears.
- (2) The functional term "protective group" as given in present **claim 12** without further chemical specification is unclear, because it does not allow a clear rendering of the scope of said claim.

THIS PAGE BLANK (USPTO)

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/EP99/10176

(3) The second reaction scheme of present **claim 15** is not clear with respect to the moiety $H_2(?)P$ in compound (XV). The same holds for the similar scheme on page 20 of the present description.

The present description contains on page 4, line 31 an unclarity with respect to the formulation "whether pharmaceutically acceptable or not...". It is pointed out, that salts which are not pharmaceutically acceptable do not solve the problem posed and therefore should not have been made part of the present alleged invention.

THIS PAGE BLANK (USPTO)

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 99/10176

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D471/20 A61K31/55 A61K31/438 A61P37/00 C07D495/22
C07D487/20 C07D498/20 C07D519/00 //(C07D471/20, 235:00,
223:00, 221:00), (C07D495/22, 333:00, 235:00, 223:00, 221:00),

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 97 24356 A (JANSSEN PHARMACEUTICA NV ;) 10 July 1997 (1997-07-10) cited in the application page 14, line 25 - line 29; claims 1,8 ---	1,10
A	EP 0 518 434 A (JANSSEN PHARMACEUTICA NV) 16 December 1992 (1992-12-16) page 27, line 7 - line 13; claims 1,7 ---	1,10
A	EP 0 393 738 A (JANSSEN PHARMACEUTICA NV) 24 October 1990 (1990-10-24) page 15, line 15 - line 23; claim 1 -----	1,10

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

30 March 2000

Date of mailing of the international search report

17/04/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Alfaro Faus, I

THIS PAGE BLANK (USPTO)

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/10176

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 (C07D495/22, 235:00, 223:00, 221:00, 209:00), (C07D487/20, 235:00, 223:00, 223:00), (C07D471/20, 235:00, 221:00, 221:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

30 March 2000

Date of mailing of the international search report

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Alfaro Faus, I

THIS PAGE BLANK (USPTO)

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inte: .onal Application No

PCT/EP 99/10176

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9724356	A	10-07-1997	AU 716071 B	17-02-2000
			AU 1308697 A	28-07-1997
			BR 9612307 A	13-07-1999
			CA 2238817 A	10-07-1997
			CZ 9801865 A	11-11-1998
			EP 0843679 A	27-05-1998
			NO 982405 A	19-08-1998
			NZ 325845 A	29-06-1999
			PL 327136 A	23-11-1998
			SK 83098 A	11-01-1999
EP 0518434	A	16-12-1992	AU 652841 B	08-09-1994
			AU 1901192 A	12-01-1993
			CA 2102889 A	14-12-1992
			CN 1068116 A,B	20-01-1993
			WO 9222553 A	23-12-1992
			EP 0588859 A	30-03-1994
			FI 935557 A	10-12-1993
			HR 920156 A	31-12-1995
			HU 70428 A	30-10-1995
			IL 101851 A	14-05-1996
			JP 6507890 T	08-09-1994
			MX 9202860 A	01-12-1992
			NO 934493 A	04-01-1994
			NZ 242775 A	28-03-1995
			PL 170376 B	31-12-1996
			US 5461050 A	24-10-1995
			ZA 9204327 A	13-12-1993
			ZM 2892 A	25-05-1994
EP 0393738	A	24-10-1990	AT 114653 T	15-12-1994
			AU 615612 B	03-10-1991
			AU 5295190 A	11-10-1990
			CA 2013892 A	07-10-1990
			CN 1046161 A,B	17-10-1990
			DE 69014385 D	12-01-1995
			DE 69014385 T	20-04-1995
			DK 393738 T	16-01-1995
			ES 2067645 T	01-04-1995
			FI 95702 B	30-11-1995
			GR 3015154 T	31-05-1995
			HU 58324 A	28-02-1992
			IE 65460 B	01-11-1995
			IL 94008 A	18-02-1997
			JP 2290874 A	30-11-1990
			NO 174851 B	11-04-1994
			NZ 233088 A	25-10-1991
			PT 93671 A,B	20-11-1990
			RU 2030415 C	10-03-1995
			US 5272150 A	21-12-1993
			ZA 9002664 A	24-12-1991

THIS PAGE BLANK (USPTO)

PATENT COOPERATION TREATY

PCT

REC'D 04 DEC 2000

WIPO PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)



Applicant's or agent's file reference JAB 1442-PCT	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/EP99/10176	International filing date (day/month/year) 15/12/1999	Priority date (day/month/year) 19/12/1998
International Patent Classification (IPC) or national classification and IPC C07D471/20		
Applicant JANSSEN PHARMACEUTICA N.V. et al.		

- This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
- This REPORT consists of a total of 7 sheets, including this cover sheet.
 - ☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of sheets.

- This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☒ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand 20/05/2000	Date of completion of this report 29.11.2000
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer Stroeter, T Telephone No. +49 89 2399 8088 

THIS PAGE BLANK (USPTO)

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/EP99/10176

I. Basis of the report

1. This report has been drawn on the basis of *(substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments (Rules 70.16 and 70.17).):*

Description, pages:

1-53 as originally filed

Claims, No.:

1-15 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

THIS PAGE BLANK (USPTO)

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/EP99/10176

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims	3, 8, 10-13, 15
	No:	Claims	1, 2, 4-7, 9, 14
Inventive step (IS)	Yes:	Claims	3, 8, 10-13, 15
	No:	Claims	
Industrial applicability (IA)	Yes:	Claims	1-15
	No:	Claims	

2. Citations and explanations
see separate sheet

VII. Certain defects in the international application

The following defects in the form or contents of the international application have been noted:
see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:
see separate sheet

THIS PAGE BLANK (USPTO)

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/EP99/10176

Re Item V

Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1 Subject-matter of the independent claims

The present application refers to 4-(imidazoazepine)piperidine spiro derivatives (independent claims 1, 9 and 12), their preparation (independent claims 14 and 15), pharmaceutical compositions (independent claim 10) comprising such compounds and the preparation of such compositions (independent claim 11) .

2 Prior art documents

Reference is made to the following documents. The given numbering will be adhered to in the rest of the procedure:

D1: WO 97 24356 A (JANSSEN PHARMACEUTICA NV ;) 10 July 1997 (1997-07-10), cited in the application

D2: EP-A-0 518 434 (JANSSEN PHARMACEUTICA NV) 16 December 1992 (1992-12-16)

D3: EP-A-0 393 738 (JANSSEN PHARMACEUTICA NV) 24 October 1990 (1990-10-24)

3 Novelty (Article 33(2) PCT)

D2 and D3 disclose related compounds having antihistaminic activity but without a spiro moiety and are therefore not relevant to the question of novelty.

D1, however, mentions on page 12, first reaction scheme, a group of compounds of formula (III), in particular formula (III-a-2-1), which overlap with the compounds as claimed in present **claim 1** if present L = H and n = 1 with present A-B, Z (corresponds to Z resp. Z¹ of D1), R¹ (corresponds to R⁴ of D1) and R² (corresponds to R⁵ of D1) having partially similar specifications.

THIS PAGE BLANK (USPTO)

Therefore D1 takes away the novelty of present claim 1 and of dependent **claims 2, 4 to 7** and independent **claims 9 and 14** by consequence.

Claims 3, 12 and consequently, 13 and 15 are novel due to the exclusion of the case $L = H$. Present **claim 8** names specific compounds not comprised in the group of compounds of formula (III-a-2-1) and is novel, too.

Present **claims 10 and 11** which are directed to pharmaceutical compositions and their preparation are novel, because the compounds have so far not been used as ingredients in such compositions.

At present it must be stated that the present application does not fulfil the requirements of Article 33(2) PCT.

4 Inventive step (Article 33(3) PCT)

On condition that the present set of claims is harmonized with Article 33(2) PCT by the Applicant, subject-matter of said claims can be at present regarded as inventive in view of D1, D2 and D3, because by revealing compounds of formula (I), the present application gives a non-obvious solution to the problem of how to provide further antihistaminic compounds.

D1 reveals the structurally closest compounds, but no antihistaminic activity is described for said compounds. Therefore D2 (or alternatively D3) is to be seen as closest prior art document. The presence of the parental system containing the spiro configuration is regarded as a major structural difference to the compounds of document D2 (resp. D3) and therefore it could not be foreseen by the skilled man that the presently claimed compounds would be active as described and therefore, the claims in question are to be seen as involving an inventive step according to Article 33(3) PCT.

THIS PAGE BLANK (USPTO)

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/EP99/10176

5 Industrial applicability (Article 33(4) PCT)

The subject-matter of the present set of claims 1 to 15 is in accordance with the requirements of Article 33(4) PCT.

Re Item VII

Certain defects in the international application

(1) To meet the requirements of Rule 5.1(a)(ii) PCT, the documents D2 and D3 should have been identified in the description and the relevant background art disclosed therein should have been briefly discussed.

(2) When entering the regional phase at the EPO, the expression "hereby incorporated" (page 3, line 20) should be deleted with respect to the EPC-Guidelines C-II, 4.18/ C-III, 4.3a.

Re Item VIII

Certain observations on the international application

Concerning clarity of the claims (Article 6 PCT) as filed by the Applicant, her attention is drawn to the following objections:

(1) The functional term "prodrug" in **claims 1 and 8** leaves the reader in doubt about the structural feature to which said term refers and causes lack of clarity (Article 6 PCT) in said claim. Therefore this term has to be excelled from those claims and from the present description whenever it appears.

(2) The functional term "protective group" as given in present **claim 12** without further chemical specification is unclear, because it does not allow a clear rendering of the scope of said claim.

THIS PAGE BLANK (USPTO)

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/EP99/10176

(3) The second reaction scheme of present **claim 15** is not clear with respect to the moiety $H_2(?)P$ in compound (XV). The same holds for the similar scheme on page 20 of the present description.

The present description contains on page 4, line 31 an unclarity with respect to the formulation "whether pharmaceutically acceptable or not...". It is pointed out, that salts which are not pharmaceutically acceptable do not solve the problem posed and therefore should not have been made part of the present alleged invention.

THIS PAGE BLANK (USPTO)

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau




71442

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁷ : C07D 471/20, A61K 31/55, 31/438, A61P 37/00, C07D 495/22, 487/20, 498/20, 519/00 // (C07D 471/20, 235:00, 223:00, 221:00) (C07D 495/22, 333:00, 235:00, 223:00, 221:00)</p>	<p>A1</p>	<p>(11) International Publication Number: WO 00/37470</p> <p>(43) International Publication Date: 29 June 2000 (29.06.00)</p>
<p>(21) International Application Number: PCT/EP99/10176</p> <p>(22) International Filing Date: 15 December 1999 (15.12.99)</p> <p>(30) Priority Data: 98204347.3 19 December 1998 (19.12.98) EP</p> <p>(71) Applicant (for all designated States except US): JANSSEN PHARMACEUTICA N.V. [BE/BE]; Patent Department, Turnhoutseweg 30, B-2340 Beerse (BE).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): JANSSENS, Frans, Ed- uard [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). LEENAERTS, Joseph, Elisabeth [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE).</p> <p>(74) Agent: QUAGHEBEUR, Luc; Janssen Pharmaceutica N.V., Patent Department - ext 3547, Turnhoutseweg 30, B-2340 Beerse (BE).</p>		<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>

(54) Title: ANTIHISTAMINIC SPIRO COMPOUNDS



(57) Abstract

This invention concerns the compounds of formula (I) a prodrug, a *N*-oxide, an addition salt, a quaternary amine or a stereochemically isomeric form thereof wherein R^1 is hydrogen, C_{1-6} alkyl, halo, formyl, carboxyl, C_{1-6} alkyloxycarbonyl, C_{1-6} alkylcarbonyl, $N(R^3R^4)C(=O)-$, $N(R^3R^4)C(=O)N(R^5)-$, ethenyl substituted with carboxyl or C_{1-6} alkyloxycarbonyl, or C_{1-6} alkyl substituted with hydroxy, carboxyl, C_{1-6} alkyloxy, C_{1-6} alkyloxycarbonyl, $N(R^3R^4)C(=O)-$, C_{1-6} alkyl $C(=O)N(R^5)-$, C_{1-6} alkyl $S(=O)_2N(R^5)-$ or $N(R^3R^4)C(=O)N(R^5)-$ wherein each R^3 and each R^4 independently are hydrogen or C_{1-6} alkyl, and R^5 is hydrogen or hydroxy; R^2 is hydrogen, C_{1-6} alkyl, hydroxy C_{1-6} alkyl, C_{1-6} alkyloxy C_{1-6} alkyl, $N(R^3R^4)C(=O)-$, aryl or halo; n is 1 or 2; $-A-B-$ represents a bivalent radical of formula $-Y-CH=CH-$, $-CH=CH-Y-$, or $-CH=CH-CH=CH-$, wherein each hydrogen atom may independently be replaced by R^6 wherein R^6 is C_{1-6} alkyl, halo, hydroxy, C_{1-6} alkyloxy, ethenyl substituted with carboxyl or C_{1-6} alkyloxycarbonyl, hydroxy C_{1-6} alkyl, formyl, carboxyl or hydroxycarbonyl C_{1-6} alkyl, and each Y independently is a bivalent radical of formula $-O-$, $-S-$ or $-NR^7-$, wherein R^7 is hydrogen, C_{1-6} alkyl or C_{1-6} alkylcarbonyl; Z is a bivalent radical of formula $-(CH_2)_p-$, $-CH=CH-$, $-CH_2-CHOH-$, $-CH_2-O-$, $-CH_2-C(=O)-$, or $-CH_2-C(=NOH)-$, provided that the bivalent radicals are connected to the nitrogen of the imidazole ring via their $-CH_2-$ moiety; and wherein p is 1, 2, 3 or 4; L is hydrogen; C_{1-6} alkyl; C_2-6 alkenyl; C_{1-6} alkylcarbonyl; C_{1-6} alkyloxycarbonyl; C_{1-6} alkyl substituted with hydroxy, carboxyl, C_{1-6} alkyloxy, C_{1-6} alkyloxycarbonyl, aryl, aryloxy, cyano or R^8HN- wherein R^8 is hydrogen, C_{1-6} alkyl, C_{1-6} alkyloxycarbonyl, C_{1-6} alkylcarbonyl; or L represents a radical of formula $-Alk-Y-Het^1$, $-Alk-NH-CO-Het^2$ or $-Alk-Het^3$ wherein Alk represents C_{1-6} alkanediyl; Y represents O, S or NH; Het^1 , Het^2 and Het^3 each represent an optionally substituted heterocycle; for use as a medicine.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

WO 00/37470

PCT/EP99/10176

-1-


ANTI-HISTAMINIC SPIRO COMPOUNDS

The present invention is concerned with spiro compounds having antihistaminic activity. It further relates to their use as a medicine, their preparation as well as compositions comprising them.

WO 97/24356, published on 10 July 1997, discloses 4-(imidazo-azepine) piperidine spiro derivatives as intermediates in the preparation of 1-(1,2-disubstituted piperidiny)-4-(imidazo-azepine) piperidine spiro derivatives having tachykinin antagonistic activity.

Surprisingly, the 4-(imidazo-azepine) piperidine spiro derivatives of the present invention show an interesting antihistaminic activity profile.

The present invention concerns compounds of formula (I) for use as a medicine, characterized in that the compounds of formula (I) are defined as



their prodrugs, *N*-oxides, addition salts, quaternary amines and stereochemically isomeric forms wherein

R^1 is hydrogen, C_{1-6} alkyl, halo, formyl, carboxyl, C_{1-6} alkyloxycarbonyl, C_{1-6} alkyl-carbonyl, $N(R^3R^4)C(=O)-$, $N(R^3R^4)C(=O)N(R^5)-$, ethenyl substituted with carboxyl or C_{1-6} alkyloxycarbonyl, or C_{1-6} alkyl substituted with hydroxy, carboxyl, C_{1-6} alkyloxy, C_{1-6} alkyloxycarbonyl, $N(R^3R^4)C(=O)-$, C_{1-6} alkyl $C(=O)N(R^5)-$, C_{1-6} alkyl $S(=O)_2N(R^5)-$ or $N(R^3R^4)C(=O)N(R^5)-$;

wherein each R^3 and each R^4 independently are hydrogen or C_{1-4} alkyl;

R^5 is hydrogen or hydroxy;

R^2 is hydrogen, C_{1-6} alkyl, hydroxy C_{1-6} alkyl, C_{1-6} alkyloxy C_{1-6} alkyl, $N(R^3R^4)C(=O)-$, aryl or halo;

n is 1 or 2;

-A-B- represents a bivalent radical of formula



-2-

-CH=CH-Y- (a-2); or

-CH=CH-CH=CH- (a-3);

wherein each hydrogen atom in the radicals (a-1) to (a-3) may independently be replaced by R^6 wherein R^6 is selected from C_{1-6} alkyl, halo, hydroxy, C_{1-6} alkyloxy, ethenyl substituted with carboxyl or C_{1-6} alkyloxycarbonyl, hydroxycarbonyl, formyl, carboxyl and hydroxycarbonyl; each Y independently is a bivalent radical of formula -O-, -S- or -NR⁷-; wherein R^7 is hydrogen, C_{1-6} alkyl or C_{1-6} alkylcarbonyl;

Z is is a bivalent radical of formula

-(CH₂)_p- (b-1),

-CH₂-O- (b-4),

-CH=CH- (b-2),

-CH₂-C(=O)- (b-5), or

-CH₂-CHOH- (b-3),

-CH₂-C(=NOH)- (b-6),

provided that the bivalent radicals (b-3), (b-4), (b-5) and (b-6) are connected to the nitrogen of the imidazole ring via their -CH₂- moiety;

wherein p is 1, 2, 3 or 4;

L is hydrogen; C_{1-6} alkyl; C_{2-6} alkenyl; C_{1-6} alkylcarbonyl; C_{1-6} alkyloxycarbonyl;

C_{1-6} alkyl substituted with one or more substituents each independently selected from hydroxy, carboxyl, C_{1-6} alkyloxy, C_{1-6} alkyloxycarbonyl, aryl, aryloxy, cyano or R⁸HN- wherein R⁸ is hydrogen, C_{1-6} alkyl, C_{1-6} alkyloxycarbonyl, C_{1-6} alkylcarbonyl; or

L represents a radical of formula

-Alk-Y-Het¹ (c-1),

-Alk-NH-CO-Het² (c-2) or


-Alk-Het³ (c-3); wherein

Alk represents C_{1-4} alkanediyl;

Y represents O, S or NH;

Het¹, Het² and Het³ each represent furanyl, tetrahydrofuranyl, thienyl, oxazolyl, thiazolyl or imidazolyl each optionally substituted with one or two C_{1-4} alkyl substituents; pyrrolyl or pyrazolyl optionally substituted with formyl, hydroxycarbonyl, C_{1-4} alkyloxycarbonyl or with one or two C_{1-4} alkyl substituents; thiadiazolyl or oxadiazolyl optionally substituted with amino or C_{1-4} alkyl; pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl each optionally substituted with C_{1-4} alkyl, C_{1-4} alkyloxy, amino, hydroxy or halo; and Het³ may also represent 4,5-dihydro-5-oxo-1H-tetrazolyl substituted with C_{1-4} alkyl, 2-oxo-3-oxazolidinyl, 2,3-dihydro-2-oxo-1H-benzimidazol-1-yl or a radical of formula

-3-



wherein

A-Z represents S-CH=CH, S-CH₂-CH₂, S-CH₂-CH₂-CH₂, CH=CH-CH=CH, or CH₂-CH₂-CH₂-CH₂;

aryl is phenyl or phenyl substituted with 1, 2 or 3 substituents each independently selected from halo, hydroxy, C₁₋₄alkyl, polyhaloC₁₋₄alkyl, cyano, aminocarbonyl, C₁₋₄alkyloxy or polyhaloC₁₋₄alkyloxy.

The compounds of formula (I) are deemed novel provided that 5,6-dihydrospiro[imidazo[1,2-b][3]benzazepine-11[11H],4'-piperidine] and pharmaceutically acceptable addition salts thereof are not included and thus the present invention also relates to the compounds of formula (I) as defined hereinabove provided that 5,6-dihydrospiro[imidazo[1,2-b][3]benzazepine-11[11H],4'-piperidine] and pharmaceutically acceptable addition salts thereof are not included.

The term prodrug as used throughout this text means the pharmacologically acceptable derivatives, e.g. esters and amides, such that the resulting biotransformation product of the derivative is the active drug as defined in the compounds of formula (I). The reference by Goodman and Gilman (The Pharmacological Basis of Therapeutics, 8th ed., McGraw-Hill, Int. Ed. 1992, "Biotransformation of Drugs", p. 13-15) describing prodrugs generally, is hereby incorporated.

As used herein C₁₋₄alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 4 carbon atoms such as methyl, ethyl, propyl, 1-methylethyl, butyl and the like; C₁₋₆alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 6 carbon atoms such as the groups defined for C₁₋₄alkyl and pentyl, hexyl, 2-methylpropyl, 2-methylbutyl and the like; C₂₋₆alkenyl as a group or part of a group defines straight and branched chain hydrocarbon radicals containing one double bond and having from 2 to 6 carbon atoms such as ethenyl, 2-propenyl, 2-butenyl, 2-pentenyl, 3-pentenyl, 3-methyl-2-butenyl, 3-hexenyl and the like.

As used herein before, the term (=O) forms a carbonyl moiety when attached to a carbon atom and a sulfonyl moiety when attached twice to a sulfur atom. The term (=NOH) forms a hydroxylimine moiety when attached to a carbon atom.

The term halo is generic to fluoro, chloro, bromo and iodo. As used in the foregoing and hereinafter, polyhaloC₁₋₄alkyl as a group or part of a group is defined as mono- or polyhalosubstituted C₁₋₄alkyl, in particular methyl with one or more fluoro atoms, for example, difluoromethyl or trifluoromethyl. In case more than one halogen atoms are
5 attached to an alkyl group within the definition of polyhaloC₁₋₄alkyl, they may be the same or different.

When any variable (e.g. R³, R⁴ etc.) occurs more than one time in any constituent, each
10 definition is independent.

It will be appreciated that some of the compounds of formula (I), their prodrugs, N-oxides, addition salts, quaternary amines and stereochemically isomeric forms may contain one or more centers of chirality and exist as stereochemically isomeric forms.

15 The term "stereochemically isomeric forms" as used hereinbefore defines all the possible stereoisomeric forms which the compounds of formula (I), their prodrugs, N-oxides, addition salts, quaternary amines or physiologically functional derivatives may possess. Unless otherwise mentioned or indicated, the chemical designation of compounds denotes the mixture of all possible stereochemically isomeric forms, said
20 mixtures containing all diastereomers and enantiomers of the basic molecular structure as well as each of the individual isomeric forms of formula (I), their prodrugs, N-oxides, addition salts or quaternary amines substantially free, *i.e.* associated with less than 10%, preferably less than 5%, in particular less than 2% and most preferably less than 1% of the other isomers. Stereochemically isomeric forms of the compounds of
25 formula (I) are obviously intended to be embraced within the scope of this invention.

For therapeutic use, the addition salts of the compounds of formula (I) are those wherein the counterion is pharmaceutically acceptable. However, salts of acids and bases which are not-pharmaceutically acceptable may also find use, for example, in the
30 preparation or purification of a pharmaceutically acceptable compound. All salts, whether pharmaceutically acceptable or not are included within the ambit of the present invention.

The pharmaceutically acceptable acid and base addition salts as mentioned hereinabove
35 are meant to comprise the therapeutically active non-toxic acid and base addition salt forms which the compounds of formula (I) are able to form. The pharmaceutically acceptable acid addition salts can conveniently be obtained by treating the base form with such appropriate acid. Appropriate acids comprise, for example, inorganic acids

such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid, sulfuric, nitric, phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic (i.e. ethanedioic), malonic, succinic (i.e. butanedioic acid), maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, *p*-toluenesulfonic, cyclamic, salicylic, *p*-aminosalicylic, pamoic and the like acids.

Conversely said salt forms can be converted by treatment with an appropriate base into the free base form.

10

The compounds of formula (I) containing an acidic proton may also be converted into their non-toxic metal or amine addition salt forms by treatment with appropriate organic and inorganic bases. Appropriate base salt forms comprise, for example, the ammonium salts, the alkali and earth alkaline metal salts, e.g. the lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g. the benzathine, *N*-methyl-D-glucamine, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like.

15

The term addition salt as used hereinabove also comprises the solvates which the compounds of formula (I) as well as the salts thereof, are able to form. Such solvates are for example hydrates, alcoholates and the like.

20

Some of the compounds of formula (I) may also exist in their tautomeric form. Such forms although not explicitly indicated in the above formula are intended to be included within the scope of the present invention.

25

An interesting group of compounds consists of those compounds of formula (I) wherein L is hydrogen, C₁₋₆alkyl, C₁₋₆alkylcarbonyl, C₁₋₆alkyloxycarbonyl or C₁₋₆alkyl substituted with hydroxy, carboxyl, C₁₋₆alkyloxy or C₁₋₆alkyloxycarbonyl;

30

Another interesting group of compounds consists of those compounds of formula (I) wherein -A-B- is a bivalent radical of formula -CH=CH-CH=CH- (a-3).

35

Also interesting compounds are those compounds of formula (I) wherein -A-B- is a bivalent radical of formula -CH=CH-Y- (a-2).

Further interesting compounds are those compounds of formula (I) wherein Z is -(CH₂)_p- (b-1), -CH=CH- (b-2), or -CH₂-O- (b-4).

Other interesting compounds are those compounds of formula (I) wherein L is hydrogen, C₁₋₆alkyl, carboxyC₁₋₆alkyl, C₁₋₆alkyloxycarbonyl, or C₁₋₆alkyloxycarbonylC₁₋₆alkyl.

- 5 Again other interesting compounds are those compounds of formula (I) wherein L is hydroxyC₁₋₆alkyl or C₁₋₆alkyl substituted with aryl and C₁₋₆alkyloxycarbonyl.

Also further interesting compounds are those compounds of formula (I) wherein R¹ is hydroxyC₁₋₆alkyl, formyl, C₁₋₆alkyloxycarbonyl, N(R³R⁴)C(=O)-, halo or hydrogen.

10

Other interesting compounds are those compounds of formula (I) wherein R¹ is C₁₋₆alkyloxyC₁₋₆alkyl.

- 15 Special compounds are those compounds of formula (I) wherein one or more of the following restrictions apply :

-A-B- is a bivalent radical of formula -CH=CH-CH=CH- (a-3) wherein each hydrogen may independently be replaced by C₁₋₆alkyl, C₁₋₆alkyloxy, halo or hydroxy;

Z is -(CH₂)_p- wherein p is 1,2,3 or 4, -CH₂-C(=O)-, -CH₂-CHOH-, -CH=CH-, -CH₂-O-;

L is hydrogen, C₁₋₆alkyl or C₁₋₆alkyloxycarbonyl;

- 20 R¹ is hydrogen, formyl, carboxyl, amide, halo, C₁₋₆alkyloxycarbonyl, C₁₋₆alkyl substituted with hydroxy, C₁₋₆alkyloxy, -NH-C(=O)-C₁₋₆alkyl, -NH-C(=O)-NH₂, -NH-SO₂-C₁₋₆alkyl;

R² is hydroxyC₁₋₆alkyl, C₁₋₆alkyloxyC₁₋₆alkyl, halo, amide.

- 25 The most preferred compounds are:

5,6-dihydrospiro[11*H*-imidazo[2,1-*b*][3]benzazepine-11,4'-piperidine]-3-carboxamide dihydrochloride (comp. 17);

1'-butyl-5,6-dihydrospiro[imidazo[2,1-*b*] [3] benzazepine-11-[11*H*],4'-piperidine] (comp. 3);

- 30 6,11-dihydro-1'-methylspiro[5*H*-imidazo[2,1-*b*][3]benzazepine-11,4'-piperidine] cyclohexylsulfamate(1:2) (comp. 1);

6,11-dihydrospiro[5-imidazo[2,1-*b*][3]benzazepine-11,4'-piperidine]-3-methanol] (E)-2-butenedioate (2:1) (comp. 18a);


3-chloro-6,11-dihydrospiro[5*H*-imidazo[2,1-*b*][3]benzazepine-11,4'-piperidine]

- 35 (E)-2-butenedioate (1:1) (comp. 20);

6,11-dihydro-3-(methoxymethyl)spiro[5*H*-imidazo[2,1-*b*][3]benzazepine-11,4'-piperidine]. (E)-2-butenedioate (1:1) (comp. 58);

- 6,11-dihydro-1'-(2-hydroxyethyl)spiro[5*H*-imidazo[2,1-*b*][3]benzazepine-11,4'-piperidine]-3-carboxamide (comp. 62);
 6,11-dihydro-1'-methylspiro[5*H*-imidazo[2,1-*b*][3]benzazepine-11,4'-piperidine]-3-carboxamide monohydrate (comp. 80);
 5 ethyl 3-(aminocarbonyl)-6,11-dihydro- α -phenylspiro[5*H*-imidazo[2,1-*b*][3]benzazepine-11,4'-piperidine]-1'-propanoate monohydrochloride (comp. 64);
 3-(aminocarbonyl)-6,11-dihydrospiro[5*H*-imidazo[2,1-*b*][3]benzazepine-11,4'-piperidine]-1'-carboxylate (comp. 79);
 spiro[10*H*-imidazo[1,2-*a*]thieno[3,2-*d*]azepine-10,4'-piperidine] (comp. 56a);
 10 6,11-dihydrospiro[5*H*-imidazo[2,1-*b*][3]benzazepine-11,4'-piperidine]-2,3-dicarboxamide dihydrochloride monohydrate (comp. 53);
 a prodrug, a *N*-oxide, an addition salt, a quaternary amine or a stereochemically isomeric form thereof.

- 15 The present invention also concerns novel compounds of formula



- their *N*-oxides, addition salts, quaternary amines and stereochemically isomeric forms, wherein
- 20 R^1 is hydrogen, C_{1-6} alkyl, halo, formyl, carboxyl, C_{1-6} alkyloxycarbonyl, C_{1-6} alkyl-carbonyl, $N(R^3R^4)C(=O)-$, $N(R^3R^4)C(=O)N(R^5)-$, ethenyl substituted with carboxyl or C_{1-6} alkyloxycarbonyl, or C_{1-6} alkyl substituted with hydroxy, carboxyl, amino, C_{1-6} alkyloxy, C_{1-6} alkyloxycarbonyl, $N(R^3R^4)C(=O)-$, $C_{1-6}alkylC(=O)N(R^5)-$, $C_{1-6}alkylS(=O)_2N(R^5)-$ or $N(R^3R^4)C(=O)N(R^5)-$;
 wherein each R^3 and each R^4 independently are hydrogen or C_{1-4} alkyl;
- 25 R^5 is hydrogen or hydroxy;
 $-A-B-$, Z , R^2 , and n are as defined for compounds of formula (I); and
 P represents a protective group for example, benzyl, or those protective groups mentioned in Chapter 7 of "Protective Groups in Organic Synthesis" by T. Greene and P. Wuyts (John Wiley & Sons, Inc. 1991),
 30 provided that 6,11-dihydro-1'-(phenylmethyl)-5*H*-spiro[imidazo[1,2-*b*][3]benzazepine-11,4'-piperidine] (E)-2-butenedioate(1:2) is not included.

The compounds of formula (II-a) are useful for the preparation of the compounds of formula (I).

Interesting compounds are those compounds of formula (II-a) wherein P is benzyl.

5


Also interesting compounds are those compounds of formula (II-a) wherein R^1 is hydrogen, halo, formyl, $N(R^3R^4)C(=O)-$, or C_{1-6} alkyl substituted with hydroxy, amino, C_{1-6} alkyl $C(=O)N(R^5)-$, C_{1-6} alkyl $S(=O)_2N(R^5)-$ or $N(R^3R^4)C(=O)N(R^5)-$.

- 10 Further interesting compounds are those compounds of formula (II-a) wherein -A-B- is a bivalent radical of formula (a-3) wherein each hydrogen atom may independently be replaced by C_{1-6} alkyl, halo, hydroxy, or C_{1-6} alkyloxy.


- 15 Again further interesting compounds are those compounds of formula (II-a) wherein Z is a bivalent radical of formula (b-1) and n is 1.

- Compounds of formula (I), can be prepared by deprotecting an intermediate of formula (II), wherein P is a protecting group, for example, benzyl, or those protective groups mentioned in Chapter 7 of "Protective Groups in Organic Synthesis" by T. Greene and P. Wuyts (John Wiley & Sons, Inc. 1991). Said deprotection reaction can be performed by, for example, catalytic hydrogenation in the presence of hydrogen and an appropriate catalyst in a reaction inert solvent. A suitable catalyst in the above reaction is, for example, platinum-on-charcoal, palladium-on-charcoal, and the like. An appropriate reaction-inert solvent for said reaction is, for example, an alcohol, e.g. methanol, ethanol, 2-propanol and the like, an ester, e.g. ethylacetate and the like, an acid, e.g. acetic acid and the like. The thus obtained deprotected compounds can optionally further be derivatized either by replacing the hydrogen on the piperidine nitrogen by a moiety belonging to L, or by introducing on the imidazole moiety a R^1 group or a R^2 group or a R^1 and R^2 group, or by derivatizing both the piperidine moiety and the imidazole moiety.

- 35 An intermediate of formula II can also first be derivatized at the imidazole moiety by introducing a R^1 group or a R^2 group or a R^1 and R^2 group, resulting in an intermediate of formula (II-a), and then be deprotected, followed optionally by a derivation at the piperidine nitrogen.




- Alternatively, compounds of formula (I), wherein Z is a bivalent radical of formula $-\text{CH}_2-\text{C}(=\text{O})-$ (b-5), said compounds being represented by formula (I-a), can be prepared by cyclizing an intermediate of formula (III) in the presence of an acid, e.g. trifluoromethanesulfonic acid and the like.



- The compounds of formula (I) may further be prepared by converting compounds of formula (I) into each other according to art-known group transformation reactions.
- 10 The compounds of formula (I) may be converted to the corresponding *N*-oxide forms following art-known procedures for converting a trivalent nitrogen into its *N*-oxide form. Said *N*-oxidation reaction may generally be carried out by reacting the starting material of formula (I) with an appropriate organic or inorganic peroxide. Appropriate inorganic peroxides comprise, for example, hydrogen peroxide, alkali metal or earth
- 15 alkaline metal peroxides, e.g. sodium peroxide, potassium peroxide; appropriate organic peroxides may comprise peroxy acids such as, for example, benzenecarboxylic acid or halo substituted benzenecarboxylic acid, e.g. 3-chlorobenzenecarboxylic acid, peroxyalkanoic acids, e.g. peroxyacetic acid, alkylhydroperoxides, e.g.

t.butyl hydro-peroxide. Suitable solvents are, for example, water, lower alcohols, e.g. ethanol and the like, hydrocarbons, e.g. toluene, ketones, e.g. 2-butanone, halogenated hydrocarbons, e.g. dichloromethane, and mixtures of such solvents.


- 5 The compounds of formula (I) wherein L is other than hydrogen, said L being represented by L_a and said compounds being represented by formula (I-b) can be prepared by reacting the compounds of formula (I) wherein L is hydrogen, said compounds being represented by formula (I-c), with a reagent of formula L_a-W_1 (IV), wherein W_1 is a suitable leaving group, such as a halo atom, e.g. chloro, or
10 mesylate, tosylate, trifluoromethanesulfonate.



- Said reaction can conveniently be conducted in a reaction-inert solvent such as, for example, an aromatic hydrocarbon, an alkanol, a ketone, an ether, a dipolar aprotic solvent, a halogenated hydrocarbon, or a mixture of such solvents. The addition of an
15 appropriate base such as, for example, an alkali or an earth alkaline metal carbonate, hydrogen carbonate, alkoxide, hydride, amide, hydroxide or oxide, or an organic base, such as, for example, an amine, may be utilized to pick up the acid which is liberated during the course of the reaction. In some instances the addition of an iodide salt, preferably an alkali metal iodide, is appropriate. Somewhat elevated temperatures and
20 stirring may enhance the rate of the reaction.


- The compounds of formula (I-b), wherein L_a is optionally substituted C_{1-6} alkyl, said L_a being represented by L_{a1} and said compounds by formula (I-b-1), can be converted into the compounds of formula (I-c) by dealkylating and subsequently carbonylating the
25 compounds of formula (I-b-1) with a reagent of formula (V), wherein W_2 represents a suitable leaving group, such as a halo atom, e.g. chloro, and L_{a2} represents C_{1-6} alkyloxycarbonyl, resulting in compounds of formula (I-b-2) and subsequently hydrolyzing the thus obtained compounds of formula (I-b-2).

-11-



- The reaction with reagent (V) is conveniently conducted by stirring and heating the starting material with the reagent in an appropriate solvent and in the presence of a suitable base. Appropriate solvents are, for example, aromatic hydro-carbons, e.g. methylbenzene, dimethylbenzene, chlorobenzene; ethers, e.g. 1,2-dimethoxyethane; methylenechloride and the like solvents. Suitable bases are, for example, alkali or earth alkaline metal carbonates, hydrogen carbonates, hydroxides, or organic bases such as, *N,N*-diethylethanamine, *N*-(1-methylethyl)-2-propanamine, and the like.
- The compounds of formula (I-b-2) are hydrolyzed in acidic or basic media following conventional methods. For example, concentrated acids such as hydrobromic, hydrochloric acid or sulfuric acid can be used, or alternatively bases such as alkali metal or earth alkaline metal hydroxides in water, an alkanol or a mixture of water-alkanol may be used. Suitable alkanols are methanol, ethanol, 2-propanol and the like.
- In order to enhance the rate of the reaction it is advantageous to heat the reaction mixture, in particular up to the reflux temperature.

- The compounds of formula (I-b-2) can also be prepared by reacting compounds of formula (I-c) with a reagent of formula (V) in the presence of a suitable base, e.g. *N,N*-diethylethanamine, in a reaction inert solvent, e.g. methylenechloride, or by reacting compounds of formula (I-c) with a reagent of formula (VI), e.g. *t*-butoxyanhydride, in a suitable solvent, such as, e.g. methylenechloride.




- The compounds of formula (I-b) wherein R¹ or R¹ and R² represent hydroxymethyl, said compounds being represented by formula (I-b-3) and (I-b-4), can be prepared by

reacting the compounds of formula (I) wherein L is L_a and R¹ and R² are hydrogen, said compounds being represented by formula (I-b-5), with formaldehyde, optionally in the presence of an appropriate carboxylic acid - carboxylate mixture such as, for example, acetic acid - sodium acetate and the like. In order to enhance the rate of the reaction, it is advantageous to heat the reaction mixture up to the reflux temperature.

The thus obtained compounds of formula (I-b-3) and (I-b-4) can be further oxidized to the corresponding aldehyde, represented by formula (I-b-6) and (I-b-7) or the corresponding carboxylic acid, represented by formula (I-b-8) and (I-b-9), by reaction with a suitable reagent such as, for example, manganese(IV)oxide, respectively, silver nitrate.


The compounds of formula (I-b-8) and (I-b-9) can further be converted in the corresponding amide, said compounds being represented by formula (I-b-10) and (I-b-11), by reaction with a suitable carbodiimide, e.g. 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, in the presence of ammonia and a suitable catalyst, e.g. *N,N*-dimethylaminopyridine, in a reaction inert solvent, e.g. methylenechloride.

-13-



The compounds of formula (I) wherein L is L_a , and R^1 or R^1 and R^2 are halo, said compounds being represented by formula (I-b-12) and (I-b-13), can be prepared by


halogenating a compound of formula (I-b-5) with an appropriate halogenating reagent in a reaction-inert solvent.



A suitable halogenating reagent in the above reaction is, for example, an *N*-halogenated amide, e.g. *N*-bromosuccinimide. A suitable reaction-inert solvent for said halogenation reaction is, for example, *N,N*-dimethylformamide, *N,N*-dimethylacetamide, methylenechloride and the like. Another suitable halogenating reagent is, for example, tetrabutylammoniumtribromide in the presence of a suitable base, e.g. sodium carbonate, in a suitable solvent, e.g. 3-methyl-2-butanone or dichloromethane/water mixture.

Compounds of formula (I-b-12) can be converted in a compound of formula (I-b-10) by reaction with $CuCN$ in the presence of a suitable solvent, e.g. *N,N*-dimethylformamide/water mixture.


The compounds of formula (I-b) wherein R^1 is C_{1-6} alkyloxycarbonyl ethenyl, said compounds being represented by formula (I-b-14), can be prepared by reacting a compound of formula (I-b-6) with a reagent of formula (VII) in the presence of a base e.g. piperidine, pyridine, and the like.




The compounds of formula (I-b-14) can further be hydrolyzed into a compound of formula (I-b) wherein R^1 is carboxyethenyl, in the presence of an acid or a base in case L_a is C_{1-6} alkyl, or in the presence of a base, in case L_a is C_{1-6} alkyloxycarbonyl.

Compounds of formula (I-b) wherein L_a is substituted ethyl, said L_a being represented


by $L_{a3}-CH_2-CH_2-$, and said compounds by formula (I-b-15) can be prepared by reacting a compound of formula (I-c) with a reagent of formula (VIII) in the presence of a suitable base, e.g. sodium bicarbonate or triethylamine, in a suitable reaction inert solvent, e.g. *N,N*-dimethylformamide or a suitable alkanol, e.g. methanol.



Compounds of formula (I-c) may also be converted into compounds of formula (I-b-15) wherein L_{a3} is hydroxy, said compounds being represented by formula (I-b-15-1) by reaction with ethylene oxide in the presence of a suitable base, e.g. triethylamine, in a suitable reaction inert solvent, such as an alkanol, e.g. methanol.




Compounds of formula (I) wherein Z is a bivalent radical of formula $-CH_2-CHOH-$ (b-3), said compounds being represented by formula (I-d), can be prepared by reducing a compound of formula (I-a) in the presence of a reducing reagent, e.g. sodium borohydride, in a reaction-inert solvent, e.g. methanol and the like.




Compounds of formula (I) wherein Z is a bivalent radical of formula $-CH_2-C(=N-OH)-$ (b-6), said compounds being represented by the formula (I-e), can be prepared by

reacting a compound of formula (I-a) with hydroxylamine or a salt thereof, e.g. the hydrochloride salt, in a reaction inert solvent, e.g. pyridine and the like.



Compounds of formula (I) wherein Z is a bivalent radical of the formula $-\text{CH}=\text{CH}-$ (b-2), said compounds being represented by formula (I-f), can be prepared by reacting a compound of formula (I-d) in the presence of an acid, e.g. methanesulfonic acid and the like.




Compounds of formula (I-b) wherein L_a is C_{1-6} alkyl substituted with C_{1-6} alkyloxy-carbonyl or C_{1-6} alkyloxycarbonyl $\text{NH}-$, can be converted into compounds of formula (I-b) wherein L_a is C_{1-6} alkyl or amino C_{1-6} alkyl by the hydrolysis reaction described above for the preparation of compounds of formula (I-c).

In the foregoing and the following preparations, the reaction mixture is worked up following art-known methods and the reaction product is isolated and, if necessary, further purified.


As described hereinabove, the intermediates of formula (II) can be derivatized at the imidazole moiety, said compounds being represented by formula (II-a), before being deprotected.

Introducing R^1 or R^1 and R^2 wherein R^1 and R^2 represent hydroxymethyl, formyl, carboxyl or amide, in a compound of formula (II) can be performed as described hereinabove for the preparation of a compound of formula (I-b-3), (I-b-4), (I-b-6), (I-b-7), (I-b-8), (I-b-9), (I-b-10), (I-b-11).


Intermediates of formula (II-a), wherein R^1 is aminomethyl and R^2 is hydrogen, said intermediates being represented by formula (II-b), can be prepared by reacting an intermediate of formula (II-c) with hydrogen and a mixture of methanol/ammonia in the presence of a suitable catalyst, for example rhodium on aluminium, in the presence of a catalyst poison, for example a thiophene solution.




Intermediates of formula (II-a), wherein R^1 is $-\text{CH}_2\text{NHC}(=\text{O})\text{NH}_2$ and R^2 is hydrogen, said intermediates being represented by formula (II-d) can be prepared by reacting an intermediate of formula (II-b) with potassium isocyanate in an appropriate acid, such as hydrochloric acid.




Intermediates of formula (II-b) can also be converted in an intermediate of formula (II-a), wherein R^1 is $-\text{CH}_2\text{NHC}(=\text{O})\text{C}_{1-6}\text{alkyl}$ and R^2 is hydrogen, said intermediate being represented by formula (II-e), by reaction with a reagent of formula (IX), wherein W_3 represents a suitable leaving group, such as a halo atom, for example chloro, in the presence of a suitable base, e.g. *N,N*-diethylethanamine, in a reaction inert solvent, such as, for example methylenechloride.



Intermediates of formula (II-b) can further be converted into an intermediate of formula (II-a), wherein R^1 is $-\text{CH}_2\text{NHS}(=\text{O})_2\text{C}_{1-6}\text{alkyl}$ and R^2 is hydrogen, said intermediate being represented by formula (II-f), by reaction with a reagent of formula (X) wherein W_4 represents a suitable leaving group, such as a halo atom, e.g. chloro, in the presence of a suitable base, for example *N,N*-diethylethanamine, in a reaction inert solvent, such as methylenechloride.



Intermediates of formula (II) can also be halogenated according to the procedure described for the preparation of the compounds of formula (I-b-12) and (I-b-13), resulting in an intermediate of formula (II-g) and (II-h).




Intermediates of formula (II-g) and (II-h) can be converted in an intermediate of formula (II-i) and (II-j) by reaction under an atmosphere of ammonia and carbonmonoxide at elevated temperatures in the presence of a suitable catalyst, e.g.

acetic acid, palladium salt, and a suitable ligand, e.g. 1,3-bis(diphenylphosphino)-propane, in a reaction inert solvent, e.g. tetrahydrofuran.


In the following paragraphs, there are described several methods of preparing the starting materials in the foregoing preparations.

- Intermediates of formula (II), wherein Z is a bivalent radical of formula $-(CH_2)_p-$ (b-1), said Z being represented by Z_1 , and said intermediates being represented by formula (II-k), can be prepared by cyclizing an alcohol of formula (XI). The intermediates of formula (II-k) may optionally be derivatized at the imidazole moiety resulting in an intermediate of formula (II-a-1) according to the procedures described for preparing a compound of formula (I-b-3), (I-b-4), (I-b-6) to (I-b-11) and an intermediate of formula (II-b) to (II-j).




- Said cyclization reaction is conveniently conducted by treating the intermediate of formula (XI) with an appropriate acid, thus yielding a reactive intermediate which cyclizes to an intermediate of formula (II-k). Appropriate acids are, for example, strong acids, e.g. methanesulfonic acid, trifluoroacetic acid, and in particular superacid systems, e.g. trifluoromethanesulfonic acid, or Lewis acids, such as $AlCl_3$ or $SnCl_4$. Obviously, only those compounds of formula II wherein P is stable under the given reaction conditions can be prepared according to the above reaction procedure.

Intermediates of formula (XI) can be prepared by reacting an imidazole derivative of formula (XII) with a ketone of formula (XIII).




Said reaction is conveniently performed in a reaction inert solvent such as, for example tetrahydrofuran, in the presence of a suitable base such as lithium diisopropylamide and butyl lithium.


Intermediates of formula (II), wherein Z represents a bivalent radical of formula $-(CH_2)_p-$ (b-1), or $-CH_2-O-$ (b-4), said Z being represented by Z_2 , and said intermediates being represented by formula (II-1), can also be prepared by reacting a tricyclic moiety of formula (XIV) with a reagent of formula (XV), wherein W_5 represents a suitable leaving group, e.g. a halo atom, such as chloro, under an inert atmosphere in a reaction inert solvent, such as tetrahydrofuran, in the presence of a suitable base such as, for example, lithium diisopropylamide and butyl lithium. The intermediates of formula (II-1) may optionally be derivatized at the imidazole moiety resulting in an intermediate of formula (II-a-2) according to the procedures described for preparing a compound of formula (I-b-3), (I-b-4), (I-b-6) to (I-b-11) and an intermediate of formula (II-b) to (II-j).



Intermediates of formula (XIV) can be prepared by cyclizing an intermediate of formula (XVI), according to the procedure described for the preparation of intermediates of formula (II-k).




Intermediates of formula (XVI) can be prepared by reduction from the corresponding aldehydes, said intermediates being represented by formula (XVII).




Said reduction can be conducted in a suitable solvent, such as, for example methanol, in the presence of a suitable reducing agent, such as sodium borohydride.

Intermediates of formula (XVI) can also be prepared by reacting an intermediate of formula (XVIII) with formol 38% solution under pressure.




- Alternatively, the tricyclic moieties of formula (XIV), wherein Z represents a bivalent radical of formula $-\text{CH}_2-$, said Z being represented by Z_3 , and said tricyclic moieties being represented by formula (XIV-a), may also be prepared by first cyclizing an intermediate of formula (XVII) wherein Z_2 represents Z_3 , said intermediate being represented by formula (XVII-a), by treating said intermediate with an appropriate acid, e.g. trifluoroacetic acid, leading to an intermediate of formula (XIX), followed by reduction in the presence of a suitable reducing agent.




- Said reduction reaction can be performed in the presence of hydrogen and an appropriate catalyst in a reaction inert solvent. A suitable catalyst in the above reaction is, for example, platinum-on-charcoal, palladium-on-charcoal, and the like. An appropriate reaction inert solvent for said reaction is, for example, an alcohol, e.g. methanol, ethanol, 2-propanol and the like, an ester, e.g. ethylacetate and the like, an acid, e.g. acetic acid and the like.

- Intermediates of formula (III) can be prepared by reacting an intermediate of formula (XX) with a reagent of formula (XXI), wherein W_6 represents a suitable leaving group, such as a halo atom, e.g. chloro, in the presence of a suitable base, e.g. sodium hydride, in a reaction inert solvent, e.g. *N,N*-dimethylformamide and the like.




Intermediates of formula (XX), wherein R^1 and R^2 are hydrogen, said intermediates being represented by formula (XX-a), can be prepared by debenzylating an intermediate of formula (XXII).




- 5 Said debenzylation reaction can be performed by, for example, catalytic hydrogenation in the presence of hydrogen and an appropriate catalyst in a reaction inert solvent. A suitable catalyst in the above reaction is, for example, platinum-on-charcoal, palladium-on-charcoal, and the like. An appropriate reaction inert solvent for said reaction is, for example, an alcohol, e.g. methanol, ethanol, 2-propanol and the like, an ester, e.g. ethylacetate and the like, an acid, e.g. acetic acid and the like.
- 10

Intermediates of formula (XXII) can be prepared by imidazole formation out of an intermediate of formula (XXIII) in an acid, such as hydrochloric acid.




- 15 Intermediates of formula (XXIII) can be prepared by reacting an intermediate of formula (XXIV) with 2,2-dimethoxyethylamine in a reaction inert solvent, such as, for example *N,N*-dimethylformamide and the like.




Intermediates of formula (XXIV) can be prepared by reacting an intermediate of

formula (XXV) with thionylchloride.



Intermediates of formula (XXV) can be prepared by substituting an intermediate of formula (XXVI) with benzylamine in the presence of a suitable base, e.g. *N,N*-diethylethanamine, in a reaction inert solvent, e.g. methylenechloride and the like.

5



Pure stereochemically isomeric forms of the compounds of formula (I) may be obtained by the application of art-known procedures. Diastereomers may be separated by physical methods such as selective crystallization and chromatographic techniques, e.g., counter-

10

The compounds of formula (I) as prepared in the hereinabove described processes are generally racemic mixtures of enantiomers which can be separated from one another following art-known resolution procedures. The racemic compounds of formula (I) which are sufficiently basic or acidic may be converted into the corresponding diastereomeric salt forms by reaction with a suitable chiral acid, respectively chiral base. Said diastereomeric salt forms are subsequently separated, for example, by selective or fractional crystallization and the enantiomers are liberated therefrom by alkali or acid. An alternative manner of separating the enantiomeric forms of the compounds of formula (I) involves liquid chromatography, in particular liquid chromatography using a chiral stationary phase. Said pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically. Preferably if a specific stereoisomer is desired, said compound will be synthesized by stereospecific methods of preparation. These methods will advantageously employ enantiomerically pure starting materials.

25

A number of intermediates and starting materials are commercially available or are known compounds which may be prepared according to conventional reaction procedures generally known in the art. For example, the preparation of 1-(1-phenyl-ethyl)-1*H*-imidazole is described in WO 92/22551.

The compounds of formula (I), their prodrugs, *N*-oxides, addition salts, quaternary amines and stereochemically isomeric forms possess useful pharmacological properties. In particular they are active antihistaminic agents, which activity can be demonstrated by for instance the 'Histamine - induced Lethality in Guinea Pigs' test (Arch. Int. Pharmacodyn. Ther., 251, 39-51, 1981), 'Protection of Rats from Compound 48/80 - induced Lethality' test (Arch. Int. Pharmacodyn. Ther., 234, 164-176, 1978), and 'Ascaris Allergy in Dogs' test (Arch. Int. Pharmacodyn. Ther., 251, 39-51, 1981 and Drug Dev. Res., 8, 95-102, 1986).

Some of the intermediates of formula (II-a) also have interesting pharmacological properties.

The compounds of the present invention have a selective binding affinity for the H₁ receptor, more in particular, they have a very low affinity for the 5HT_{2A} serotonin receptor and the 5HT_{2C} serotonin receptor. This dissociation between the H₁ receptor binding affinity and the 5HT_{2c} and 5HT_{2A} receptor binding affinity renders it unlikely for the present compounds to cause appetite stimulation and inappropriate weight gain reported for some other H₁-antagonists.

An important asset of the present compounds is their lack of sedating properties at therapeutic dose levels, a troublesome side effect associated with many antihistaminic and antiallergic compounds. The non-sedating properties of the present compounds can be demonstrated, for example, by the results obtained in studying the sleep - wakefulness cycle of the rat (Psychopharmacology, 97, 436-442, (1989)) and the state of vigilance using EEG power spectra in wake rats (Sleep Research 24A, 118, (1995)).

The compounds of the present invention are also characterized by the absence of relevant cardio-hemodynamic and electrophysiological effects such as QTc prolongation.

An additional advantage of some of the present compounds is that they exhibit little or no metabolic transformations in animal and human liver, thus indicating a low risk for metabolic interactions.

Another interesting feature of the present compounds relates to their fast onset of action and the favorable duration of their action. The latter characteristic may enable the administration of the compound once daily.

5

The present compounds have a favorable physicochemical profile, particularly in terms of solubility and chemical stability.

10 In view of their physicochemical and pharmacological properties, the compounds of formula (I), their prodrugs, *N*-oxides, addition salts, quaternary amines and stereochemically isomeric forms thereof are very useful in the treatment of a broad range of allergic diseases such as, for example, allergic rhinitis, allergic conjunctivitis, chronic urticaria, pruritis, allergic asthma and the like.

15 Also in view of their useful physicochemical and pharmacological properties the subject compounds may be formulated into various pharmaceutical forms for administration purposes. To prepare the antiallergic compositions of this invention, an effective amount of the particular compound, in base or acid addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable
20 carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are, desirably as unitary dosage forms, administered orally, parenterally, percutaneously, rectally or topically for systemic action, or for topical action. In case of oral liquid pharmaceutical preparations, comprising solutions, suspensions, syrups, elixirs and
25 emulsions, any of the usual pharmaceutical media, such as, for example, water, glycols, oils, alcohols and the like, may be employed, whereas in case of oral solid pharmaceutical preparations, comprising powders, pills, capsules and tablets, excipients such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like may be employed. Because of their ease in administration, tablets and capsules
30 represent the most advantageous oral unit dosage forms, in which case solid pharmaceutical carriers are obviously employed. In case of injectable pharmaceutical compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, such as semipolar solvents, may be included, for example, to aid solubility. Examples of carriers for injectable solutions comprise saline solution,
35 glucose solution or a mixture of saline and glucose solution. Injectable solutions containing compounds of the aforementioned formulas may also be formulated in an oil for prolonged action. Appropriate oils for this purpose are, for example, peanut oil, sesame oil, cottonseed oil, corn oil, soy bean oil, synthetic glycerol esters of long chain

fatty acids and mixtures of these and other oils. For the preparation of injectable suspensions, appropriate liquid carriers, suspending agents and the like may be employed. In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wettable agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not cause any significant deleterious effects on the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions. These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on, as an ointment or as a gel. In case of pharmaceutical compositions for rectal administration, any of the usual excipients may be employed, comprising fat based and water soluble excipients, optionally combined with suitable additives, such as suspending or wetting agents. As appropriate compositions for topical application there may be cited all compositions usually employed for topically administering drugs e.g. creams, gellies, dressings, lotions, shampoos, tinctures, pastes, ointments, salves, ovules, powders, inhalations, nose sprays, eye drops and the like. Semisolid compositions such as salves, creams, gellies, ointments and the like will conveniently be used, but application of said compositions may be, for example, also by aerosol, e.g. with a propellant such as nitrogen, carbon dioxide, a freon, or without a propellant such as a pump spray or drops.

It is especially advantageous to formulate the aforementioned pharmaceutical compositions in unit dosage form for ease of administration and uniformity of dosage. Unit dosage form as used in the specification and claims herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such unit dosage forms are tablets (including scored or coated tablets), capsules, pills, powder packets, suppositories, ovules, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.

The present invention also relates to a method of treating warm-blooded animals suffering from allergic diseases by administering to said warm-blooded animals an effective anti-allergic amount of a compound of formula (I), a prodrug, *N*-oxide, addition salt, quaternary amine or stereochemically isomeric form thereof.

The present invention further relates to the compounds of formula (I), their prodrugs, *N*-oxides, addition salts, quaternary amines and stereochemically isomeric forms

thereof for use as a medicine, and hence, the use of the present compounds for the manufacture of a medicament for treating warm-blooded animals suffering from allergic diseases is also part of the present invention.

5 In general it is contemplated that an effective antiallergic amount would be from about 0.001 mg/kg to about 2 mg/kg body weight, and more preferably from about 0.01 mg/kg to about 0.5 mg/kg body weight. In any event, an effective antiallergic amount may depend on the type and severity of the affliction to be treated and the evaluation of the physician prescribing the treatment with the subject drugs.

10 The following examples are intended to illustrate the scope of the present invention.

Experimental part

Hereinafter, THF means tetrahydrofuran, DIPE means diisopropyl ether, DMF means

15 *N,N*-dimethylformamide, DIPA means diisopropyl amine

A. Preparation of intermediate compounds

Example A1

a) A mixture of DIPA (1.4 mol) in THF (3000ml) was stirred at -70°C under N₂ flow. Butyllithium 2.5 M/hexane (1.3 mol) was added portionwise at a temperature below -
20 40°C. The mixture was stirred at -70°C for 15 min. 1-phenylethyl-1*H*-imidazole (1 mol) dissolved in THF was added dropwise at a temperature below -55°C. The mixture was stirred at -70°C for 1 hour. 1-(phenylmethyl)-4-piperidinone (1.2 mol) dissolved in THF was added dropwise at a temperature below -55°C. The mixture was stirred at -70°C for 1 hour, then brought to room temperature, stirred at room
25 temperature overnight and decomposed with H₂O. The organic solvent was evaporated. The aqueous concentrate was extracted with CH₂Cl₂. The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated. The residue was crystallized from DIPE (1100ml). The precipitate was filtered off, washed with DIPE and dried, yielding 271g of 4-[1-(2-phenylethyl)-1*H*-imidazol-2-yl]-1-(phenylmethyl)-4-
30 piperidinol (75%) (interm. 1).

b) A mixture of intermediate (1) (0.75 mol) in trifluoromethanesulfonic acid (1500ml) was stirred at 65°C for 120 hours, then cooled, poured out on ice, alkalinized with NaOH 50% and extracted with CH₂Cl₂. The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated. The residue was crystallized from
35 DIPE/CH₃CN (99/1) (1200ml). The precipitate was filtered off and dried, yielding 169.6g of 5,6-dihydro-1'-(phenylmethyl)spiro[11*H*-imidazo[2,1-*b*][3]benzazepine-11,4'-piperidine] (66%) (interm. 2).

Example A2

1-(phenylmethyl)-4-[1-(phenylmethyl)-1*H*-imidazol-2-yl]-4-piperidinol (0.124 mol) and AlCl₃ (0.31 mol) were stirred in a melt at 120°C for 1h. The mixture was cooled, AlCl₃ (0.31 mol) was added and the mixture was stirred at 120°C for 1h. The mixture was poured into ice, alkalized with NaOH 50% and extracted with CH₂Cl₂. The organic layer was dried (MgSO₄), filtered off and evaporated. The residue was purified by HPLC (eluent : CH₂Cl₂/(CH₃OH/NH₃) 99/1). The pure fractions were collected and evaporated. The residue was converted into the hydrochloric acid salt (1:2) in (C₂H₅)₂O, yielding 0.91g of 1'-(phenylmethyl)spiro[imidazo[1,2-*b*]isoquinoline-10[5*H*],4'-piperidine]dihydrochloride.dihydrate (2%) (interm. 3; mp. 161.2 °C).

Example A3

a) A mixture of intermediate (2) (0.09 mol) in CH₂Cl₂ (1000ml) was cooled to 0°C. 1-bromo-2,5-pyrrolidinedione (0.09 mol) was added portionwise over a 1-hour period. The organic layer was separated, washed with H₂O, dried, filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH 97.5/2.5 to 95/5). A pure fraction was collected and the solvent was evaporated. The residue was dissolved in ethanol and converted into the (E)-2-butenedioic acid salt (1:1). The precipitate was filtered off and dried, yielding 17.3g of 3-bromo-5,6-dihydro-1'-(phenylmethyl)spiro[11*H*-imidazo[2,1-*b*][3]-benzazepine-11,4'-piperidine (E)-2-butenedioate(1:1) (36%) (interm. 4). Part of this fraction (16.5g) was taken up in H₂O, K₂CO₃ and CH₂Cl₂. The mixture was separated into its layers. The aqueous layer was extracted with CH₂Cl₂. The combined organic layer was dried (MgSO₄), filtered and the solvent was evaporated, yielding 12.9g of 3-bromo-5,6-dihydro-1'-(phenylmethyl)spiro[11*H*-imidazo[2,1-*b*][3]benzazepine-11,4'-piperidine (interm. 4a).

b) A mixture of intermediate (4a) (0.21 mol), 1,3-propanediylbis[diphenylphosphine] (2.5 g) and acetic acid, palladium(2+) salt (0.68 g) in THF (567 ml) was stirred in an autoclave at 150°C for 16 hours under NH₃ (10 atm) and CO (30 atm). The mixture was filtered and the filtrate was evaporated. This residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/C₂H₅OH 100/0 over 46 min to 70/30). The pure fractions were collected and the solvent was evaporated, yielding 36 g of 5,6-dihydro-1'-(phenylmethyl)spiro[11*H*-imidazo[2,1-*b*][3]benzazepine-11,4'-piperidine]-3-carboxamide (44%) (interm. 5).

Example A4

a) A mixture of intermediate (2) (0.16 mol) and sodium acetate (45g) in formol 38% (300ml) and acetic acid (30ml) was stirred and refluxed for 6 hours, then cooled,

poured out on ice and alkalized with a NaOH solution. The precipitate was filtered off and purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH 99/1). The desired fractions were collected and the solvent was evaporated. The residue was triturated in CH₃CN, filtered off and dried, yielding 13g of 5,6-dihydro-1'-(phenylmethyl)spiro[11*H*-imidazo[2,1-*b*][3]benzazepine-11,4'-piperidine]-3-methanol (interm. 6).

b) A mixture of intermediate (6) (0.032 mol) and MnO₂ (65g) in chloroform (250ml) was stirred and refluxed for 2 hours, then cooled, filtered over dicalite and the filtrate was evaporated, yielding 11g of 5,6-dihydro-1'-(phenylmethyl)spiro[11*H*-imidazo[2,1-*b*][3]benzazepine-11,4'-piperidine]-3-carboxaldehyde (interm. 7).

c) A mixture of intermediate (7) (0.0296 mol) in CH₃OH/NH₃ (500ml) was hydrogenated at 50°C with Rh/Al₂O₃ 5% (2g) as a catalyst in the presence of a thiophene solution (2ml). After uptake of H₂ (1 equiv), the catalyst was filtered off and the filtrate was evaporated, yielding 11g of 5,6-dihydro-1'-(phenylmethyl)spiro[11*H*-imidazo[2,1-*b*][3]benzazepine-11,4'-piperidine]-3-methanamine (interm. 8). Part of this fraction (1g) was purified by column chromatography over silica gel (eluent: CH₂Cl₂/(CH₃OH/NH₃) 95/5). The pure fractions were collected and the solvent was evaporated. The residue was dissolved in 2-propanol and converted into the hydrochloric acid salt (1:3) with 2-propanol/HCl. The mixture was crystallized from DIPE. The precipitate was filtered off and dried, yielding 0.8g of 5,6-dihydro-1'-(phenylmethyl)spiro[11*H*-imidazo[2,1-*b*][3]benzazepine-11,4'-piperidine]-3-methanamine hydrochloride (1:3) hydrate (1:1) (interm. 8a).

d) A mixture of intermediate (8) (0.0198 mol) in HCl 1N (50ml) was stirred at 50°C. KOCN (0.023 mol) was added portionwise (4x0.5g). The mixture was stirred at 50°C for 2 hours, then cooled, neutralized with a NaHCO₃ solution and extracted with CH₂Cl₂. The organic layer was separated, washed with H₂O, dried, filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/(CH₃OH/NH₃) 95/5). The pure fractions were collected and the solvent was evaporated, yielding 4.3g of *N*-[[5,6-dihydro-1'-(phenylmethyl)spiro[11*H*-imidazo[2,1-*b*][3]benzazepin]-3-yl]methyl]methyl]urea (interm. 9)

Example A5

A mixture of intermediate (8) (0.0295 mol) and triethylamine (0.035 mol) in CH₂Cl₂ (140ml) was stirred at room temperature. A solution of acetyl chloride (0.03 mol) in CH₂Cl₂ (10ml) was added dropwise. The mixture was stirred at room temperature for 1 hour and poured out into H₂O. K₂CO₃ (2g) was added. The mixture was extracted with CH₂Cl₂. The organic layer was separated, washed with H₂O, dried, filtered and

the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH 97/3). The pure fractions were collected and the solvent was evaporated. Part of the residue (1.3g) was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH 95/5). The pure fractions were collected and the solvent was evaporated. The residue was triturated in DIPE, filtered off and dried, yielding *N*-[[5,6-dihydro-1'-(phenylmethyl)spiro[11*H*-imidazo[2,1-*b*][3]-benzazepine-11,4'-piperidin]-3-yl]methyl]acetamide (interm. 10).

Example A6

A mixture of intermediate (8) (0.012 mol) and triethyl amine (0.015 mol) in CH₂Cl₂ (150ml) was stirred at 0°C under N₂ flow. Methanesulfonyl chloride (0.013 mol) was added dropwise. The mixture was stirred for 2 hours. H₂O was added and the mixture was extracted with CH₂Cl₂. The organic layer was separated, washed with H₂O, dried, filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH 98/2). The pure fractions were collected and the solvent was evaporated, yielding 2.1g of *N*-[[5,6-dihydro-1'-(phenylmethyl)spiro[11*H*-imidazo[2,1-*b*][3]benzazepine-11,4'-piperidin]-3-yl]methyl]methanesulfonamide (interm. 11).

Example A7

a) 1-Methyl-4-phenyl-4-piperidinecarbonyl chloride (0.49 mol) was added portionwise at room temperature to a stirring mixture of benzenemethanamine (0.49 mol) and triethyl amine (1.223 mol) in CH₂Cl₂ (2500ml). The mixture was stirred at room temperature for 1 hour. K₂CO₃ (150g) and H₂O were added. The mixture was stirred and separated into its layers. The aqueous layer was extracted with CH₂Cl₂. The combined organic layer was dried (MgSO₄), filtered and the solvent was evaporated, yielding 144g of 1-methyl-4-phenyl-*N*-(phenylmethyl)-4-piperidinecarboxamide (95%) (interm. 12).

b) A mixture of intermediate (12) (0.47 mol) in thionylchloride (750ml) was stirred and refluxed for 1 hour. The solvent was evaporated. Toluene was added twice and evaporated again, yielding 190g of *N*-[chloro(1-methyl-4-phenyl-4-piperidinyl)-methylene]benzenemethanamine monohydrochloride (100%) (interm. 13).

c) A mixture of intermediate (13) (0.47 mol) in DMF (750ml) was cooled on an ice bath. 2,2-Dimethoxyethanamine (0.54 mol) dissolved in DMF was added dropwise. The mixture was stirred at room temperature overnight. The solvent was evaporated, yielding 210g of *N*-(2,2-dimethoxyethyl)-1-methyl-4-phenyl-*N'*-(phenylmethyl)-4-piperidinecarboximidamide dihydrochloride (100%) (interm. 14).

d) A mixture of intermediate (14) (0.47 mol) in HCl 6N (1500ml) was stirred until a cloudy solution, then washed with CH₂Cl₂ (900ml), stirred at 80°C for 1 hour, cooled, alkalized with a NaOH 50% solution and extracted with CH₂Cl₂. The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated. The residue was crystallized from CH₃CN. The precipitate was filtered off and dried, yielding 38.3g of 1-methyl-4-phenyl-4-[1-(phenylmethyl)-1*H*-imidazol-2-yl]piperidine (25%) (interm. 15).

e) A mixture of intermediate (15) (0.195 mol) in methanol (350ml) was hydrogenated at room temperature for 18 hours with palladium on charcoal 10% (3g) as a catalyst. After uptake of H₂ (1 equiv), the catalyst was filtered off and the filtrate was evaporated. The residue was crystallized from CH₃CN. The precipitate was filtered off and dried, yielding 42.3g of 4-(1*H*-imidazol-2-yl)-1-methyl-4-phenylpiperidine (90%) (interm. 16).

f) A mixture of sodium hydride 60% (0.232 mol) in DMF (150ml) was stirred at room temperature. Intermediate (16) (0.145 mol) dissolved in DMF (400ml) was added dropwise. The mixture was stirred at room temperature for 1 hour. Methyl 2-chloroacetate (0.232 mol) dissolved in DMF (400ml) was added dropwise. The mixture was stirred at room temperature for 20 min, poured out into a solution of NaHCO₃ (20g) in H₂O (2000ml) and extracted with CH₂Cl₂. The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/(CH₃OH/NH₃) 95/5). The pure fractions were collected and the solvent was evaporated, yielding 40.1g of methyl 2-(1-methyl-4-phenyl-4-piperidinyl)-1*H*-imidazole-1-acetate (88%) (interm. 17).

Example A8

a) Reaction under N₂ atmosphere. A mixture of DIPA (0.455 mol) in THF (500 ml) was stirred at -78°C. Butyllithium, 2.5M/hexane (0.390 mol) was added dropwise at -40°C. The mixture was stirred for 15 min, then re-cooled to -78°C. A solution of 1-(4-phenylbutyl)-1*H*-imidazole, prepared according to the procedure described in J. Chem. Soc., Perkin Trans., 1 (1975), 17, 1670-1671, (0.325 mol) in THF (350 ml) was added dropwise at -60°C. The mixture was stirred for one hour, then re-cooled to -78°C. This mixture was added dropwise to a mixture of *N,N*-dimethylformamide (0.390 mol, dry, p.a.) in THF (500 ml), stirred at -78°C. The reaction mixture was stirred for one hour at -78°C, then allowed to warm to room temperature while stirring overnight. A saturated aqueous NH₄Cl solution (400 ml) was added and this mixture was extracted with THF. The separated organic layer was dried, filtered and the solvent

evaporated, yielding 74.2 g of 1-(4-phenylbutyl)-1*H*-imidazole-2-carboxamide (interm. 18).

b) A mixture of intermediate (18) (0.325 mol) in methanol (1400 ml) was stirred at room temperature. NaBH₄ (0.650 mol) was added portionwise and the reaction mixture was stirred for 2 hours at room temperature. The solvent was evaporated. The residue was taken up into water and this mixture was extracted with CH₂Cl₂. The separated organic layer was dried, filtered and the solvent evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH 100/0, 99/1, 97/3, 96/4, 95/5 and 93/7). The desired fractions were collected and the solvent was evaporated, yielding 49.5 g of 1-(4-phenylbutyl)-1*H*-imidazole-2-methanol (66%) (interm. 19).

c) A mixture of intermediate (19) (0.417 mol) in methanesulfonic acid (960ml) was stirred at 120°C for 40 hours, then cooled, poured out on ice and alkalized with NH₄OH. The organic layer was separated, dried, filtered and the solvent evaporated. This fraction was purified by HPLC over silica gel (eluent: CH₂Cl₂/CH₃OH 97/3). A pure fraction was collected and the solvent was evaporated. The residue was crystallized from DIPE. The precipitate was filtered off and dried, yielding 15.7g of 6,7,8,13-tetrahydro-5*H*-imidazo[2,1-*b*][3]benzazonine (18%) (interm. 20).

d) A mixture of DIPA (0.151 mol) in THF (650ml) was stirred at -78°C under N₂ flow. Butyllithium 2,5M in hexane (0.144 mol) was added dropwise at a temperature below -40°C. The mixture was stirred at -78°C for 15 min. Intermediate (20) (0.072 mol) in a small amount of THF was added dropwise at a temperature below -55°C. The mixture was stirred at -78°C for 1 hour. *N,N*-bis(2-chloroethyl)benzenemethanamine hydrochloride in a small amount of THF was added dropwise at a temperature below -50°C. The mixture was stirred at -78°C for 1 hour, allowed to warm to room temperature overnight and decomposed with H₂O. The organic solvent was evaporated. The aqueous concentrate was extracted with CH₂Cl₂. The organic layer was separated, dried, filtered and the solvent was evaporated. This fraction was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH 100/0, 99/1, 98/2, 96/4, 94/6 and 92/8). A fraction was collected and the solvent was evaporated, yielding 5,6,7,8-tetrahydro-1'-(phenylmethyl)spiro[13*H*-imidazo[2,1-*b*] [3]benzazonine-13,4'-piperidine] (interm. 21).

Example A9

A mixture of 5,10-dihydro-imidazo[1,2-*b*]isoquinoline-7,8-diol, obtained according to the procedure described in Ex.No. A8 c, (0.155 mol), phenyltrimethylammonium chloride (0.31 mol) and K₂CO₃ (0.68 mol) in DMF (400ml) was stirred at 90°C for 20

-33-

hours, cooled, poured out into H₂O and filtered over dicalite. The filtrate was separated into its layers. The organic layer was washed with H₂O, dried (MgSO₄), filtered and the solvent was evaporated. The residue was purified over silica gel on a glass filter (eluent: CH₂Cl₂/CH₃OH 100/0 to 97/3). The pure fractions were collected and the solvent was evaporated, yielding 3g of 5,10-dihydro-7,8-dimethoxyimidazo[1,2-b]isoquinoline (8.4%) (interm. 22).

Example A10


A mixture of intermediate (31) (see Table 1), prepared according to the procedure described in Ex.No. A8d, (0.01 mol) in HBr 48 % solution (60ml) was stirred and refluxed for 2 hours. The solvent was evaporated. The residue was taken up in a small amount of H₂O. The mixture was alkalized with K₂CO₃ and extracted with CH₂Cl₂/CH₃OH. The organic layer was separated, dried, filtered and the solvent was evaporated, yielding 4.3g of 5,6-dihydro-1'-(phenylmethyl)spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine]-8,9-diol (100%) (interm. 23).

Example A11

A mixture of compound (22) (0.0117 mol) and triethyl amine (0.0421 mol) in toluene (100ml) was stirred and refluxed. Ethyl carbonochloridate (0.0702 mol) was added dropwise at reflux temperature. The mixture was stirred and refluxed for 1 hour, cooled, poured out into H₂O and K₂CO₃ (15g) and separated into its layers. The aqueous layer was extracted with CH₂Cl₂. The combined organic layer was dried (MgSO₄), filtered and the solvent was evaporated. The residue was purified over silica gel on a glass filter (eluent: CH₂Cl₂/ethanol 96/4). The pure fractions were collected and the solvent was evaporated. The residue was boiled in DIPE. The precipitate was filtered off and dried, yielding 2.4g of [1'-(ethoxycarbonyl)spiro[11H-imidazo[2,1-b]-[3]benzazepine-11,4'-piperidine)-6-yl] ethyl carbonate (33%) (interm. 24).

Table 1 lists intermediates which were prepared according to one of the above mentioned examples.

Table 1



Interm. No.	Ex. No.	n	z	R1	-A-B-
25	A8d	2	-(CH ₂) ₂ -	H	-CH=CH-CH=CH-
3	A2	1	-CH ₂ -	H	-CH=CH-CH=CH-
2	A1b	1	-(CH ₂) ₂ -	H	-CH=CH-CH=CH-
26	A8d	1	-(CH ₂) ₂ -	H	-CH=CF-CH=CH-
27	A8d	1	-(CH ₂) ₂ -	H	-CH=CH-CH=CCH ₃ -
28	A8d	1	-(CH ₂) ₃ -	H	-CH=CH-CH=CH-
29	A8d	1	-(CH ₂) ₂ -	H	-COH=CH-CH=CH-
30	A8d	1	-(CH ₂) ₂ -	H	-CH=CH-COH=CH-
31	A8d	1	-(CH ₂) ₂ -	H	-CH=COCH ₃ -COCH ₃ =CH-
32	A8d	1	-O-CH ₂ -	H	-CH=CH-CH=CH-
23	A10	1	-(CH ₂) ₂ -	H	-CH=COH-COH=CH-
6	A4a	1	-(CH ₂) ₂ -	CH ₂ OH	-CH=CH-CH=CH-
7	A4b	1	-(CH ₂) ₂ -	C(=O)H	-CH=CH-CH=CH-
8	A4c	1	-(CH ₂) ₂ -	CH ₂ NH ₂	-CH=CH-CH=CH-
10	A5	1	-(CH ₂) ₂ -	CH ₂ NHC(=O)CH ₃	-CH=CH-CH=CH-
9	A4d	1	-(CH ₂) ₂ -	CH ₂ NHC(=O)NH ₂	-CH=CH-CH=CH-
5	A3b	1	-(CH ₂) ₂ -	C(=O)NH ₂	-CH=CH-CH=CH-
21	A8d	1	-(CH ₂) ₄ -	H	-CH=CH-CH=CH-
11	A6	1	-(CH ₂) ₂ -	CH ₂ NHSO ₂ CH ₃	-CH=CH-CH=CH-
33	A8d	1	-(CH ₂)-	H	-CH=COCH ₃ -COCH ₃ =CH-

B. Preparation of final compounds

Example B1 (preparative example)

5 A mixture of intermediate (2) (0.02 mol) in methanol (150ml) was hydrogenated with palladium on charcoal 10% (2g) as a catalyst at 50°C for 18 hours. After uptake of H₂ (1eq), the catalyst was filtered and the filtrate was evaporated, yielding 5,6-dihydro-spiro[11*H*-imidazo[2,1-*b*][3]benzazepine-11,4'-piperidine] (comp. 6; not claimed). This fraction was converted into the hydrochloric acid salt (1:1) in CH₃CN, yielding 5g of 5,6-dihydrospiro[imidazo[1,2-*b*][3]benzazepine-11[11*H*],4'-piperidine] monohydrochloride (86%) (comp. 6a; not claimed). A fraction obtained in said way, 10 can also be converted into the (E)-2-butenedioic acid salt.

Example B2

a) A mixture of compound (6) (0.1 mol) and *N,N*-diethylethanamine (0.13 mol) in CH₂Cl₂ (300ml) was stirred at a temperature below 10°C. Ethyl carbonochloridate 15 (0.12 mol) was added dropwise at this temperature. The mixture was allowed to warm

to room temperature and then stirred at room temperature for 1 hour. Water and K_2CO_3 (10g) were added. The mixture was separated into its layers. The aqueous layer was extracted with CH_2Cl_2 . The combined organic layer was dried ($MgSO_4$), filtered and the solvent was evaporated, yielding 35.4g of ethyl 5,6-dihydrospiro[11*H*-imidazo-

5 [2,1-*b*][3]benzazepine-11,4'-piperidine]-1'-carboxylate (100%) (comp. 4).

b) A mixture of compound (4) (0.1 mol), sodium acetate (0.3 mol) and acetic acid (0.258 mol) in formaldehyde 38% solution (165ml) was stirred and refluxed for 10 hours. The mixture was poured out into ice and a NaOH solution and extracted with CH_2Cl_2 . The organic layer was separated, dried ($MgSO_4$), filtered and the solvent was

10 evaporated. The residue was purified by column chromatography over silica gel (eluent: CH_2Cl_2 /ethanol 95/5 to 90/10). The pure fractions were collected and the solvent was evaporated, yielding 16.5g of ethyl 5,6-dihydro-3-(hydroxymethyl)spiro-

[11*H*-imidazo[2,1-*b*][3]-benzazepine-11,4'-piperidine]-1'-carboxylate (46%) (comp. 5).

c) A mixture of compound (5) (0.046 mol) and potassium hydroxide (0.46 mol) in

15 2-propanol (130ml) was stirred and refluxed for 7 hours. The solvent was evaporated. The residue was taken up in water and extracted with CH_2Cl_2 . The organic layer was separated, dried ($MgSO_4$), filtered and the solvent was evaporated, yielding 11.5g of 5,6-dihydrospiro[11*H*-imidazo[2,1-*b*][3]benzazepine-11,4'-piperidine]-3-methanol

(88%) (comp. 18). Part of this fraction (1g) was dissolved in CH_3OH and converted

20 into the (E)-2-butenedioic acid salt (2:1). The precipitate was filtered off and dried, yielding 0.6g of 5,6-dihydrospiro[11*H*-imidazo[2,1-*b*][3]benzazepine-11,4'-piperidine]-3-methanol (E)-2-butenedioic acid salt (2:1) (comp. 18a).

Example B3

A mixture of compound (6) (0.01 mol) and $(CH_2O)_n$ (0.066 mol) in methanol (150ml)

25 and thiophene 4% solution (1ml) was hydrogenated with palladium on charcoal 10% (1g) as a catalyst at 50°C. After uptake of H_2 (1eq), the catalyst was filtered and the filtrate was evaporated. The residue was taken up in $H_2O/K_2CO_3/NH_4OH$ and stirred. The mixture was extracted with CH_2Cl_2 , dried, filtered and evaporated. The residue was converted into the cyclohexanesulfamic acid salt (1:2) in 2-propanone and

30 recrystallized twice from 2-propanol, yielding 2.44g of 6,11-dihydro-1'-methyl-spiro[5*H*-imidazo[2,1-*b*][3]benzazepine-11,4'-piperidine] cyclohexylsulfamate(1:2) (40%) (comp. 1).

Example B4

a) A mixture of 1-bromobutane (0.012 mol), compound (6) (0.01 mol), Na_2CO_3

35 (0.02 mol) and potassium iodide (few crystals) in 2-butanone (200ml) was stirred and refluxed overnight. The mixture was evaporated, the residue was taken up in water and

extracted with CH_2Cl_2 . The organic layer was dried, filtered off and evaporated. The residue was purified by column chromatography over silica gel (eluent : $\text{CH}_2\text{Cl}_2/(\text{CH}_3\text{OH}/\text{NH}_3)$ 95/5). The pure fractions were collected and evaporated. The residue was converted into the hydrochloric acid salt (1:2) in 2-propanol. The precipitate was
5 filtered and dried, yielding 0.7g of 1'-butyl-5,6-dihydrospiro[imidazo[2,1-b][3]-benzazepine-11-[11*H*],4'-piperidine] dihydrochloride.hemihydrate (18%) (comp. 3).

b) A mixture of 1-(3-chloropropoxy)-4-fluorobenzene (0.018 mol), 5,6-dihydrospiro[11*H*-imidazo[2,1-b][3]benzazepine-11,4'-piperidine] (0.015 mol), Na_2CO_3 (0.015 mol) and KI (10 mg) in 4-methyl-2-pentanone (200ml) was stirred and refluxed
10 for 18 hours. The mixture was poured into water, separated and the aqueous layer was extracted with CH_2Cl_2 . The organic layer was dried (MgSO_4), filtered off and evaporated. The residue was purified on a glass filter over silica gel (eluent : $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ 90/10). The pure fractions were collected and evaporated. The residue was converted into the cyclohexylsulfamic acid salt (1:2) in 2-propanone. Yielding :
15 4.26g of 1'-[3-(4-fluorophenoxy)propyl]-5,6-dihydrospiro[imidazo[2,1-b][3]benzazepine-11-[11*H*],4'-piperidine] cyclohexylsulfamate(1:2) (37%); mp. 180°C (comp. 71).

c) A mixture of 1-chloro-3-methyl-2-butene (0.02 mol), 5,6-dihydrospiro[11*H*-imidazo[2,1-b][3]benzazepine-11,4'-piperidine] (0.015 mol), Na_2CO_3 (0.015 mol) and
20 KI (0.015 mol) in *N,N*-dimethylacetamide (150ml) was stirred at room temperature overnight. The mixture was filtered over dicalite and evaporated. The residue was taken up in $\text{CH}_2\text{Cl}_2/\text{water}$ 95/5. The precipitate was filtered off and dried. Yielding : 0.86g of 5,6-dihydro-1'-(3-methyl-2-butenyl)spiro[imidazo[2,1-b][3]benzazepine-11-[11*H*],4'-piperidine] monohydroiodide (12.7%); mp. 255.4°C (comp. 74).

d) A mixture of 1-(2-bromoethyl)-4-ethyl-1,4-dihydro-5*H*-tetrazol-5-one (0.012 mol), 5,6-dihydrospiro[11*H*-imidazo[2,1-b][3]benzazepine-11,4'-piperidine] (0.01 mol), Na_2CO_3 (0.01 mol) and KI (10 mg) in 4-methyl-2-pentanone (200ml) was stirred and
25 refluxed for 18 hours. The mixture was poured into water. The mixture was separated and the aqueous layer was extracted with 3-methyl-2-butanone, dried (MgSO_4), filtered and evaporated. The residue was purified on a glass filter over silica gel (eluent : $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ 95/5 to 93/7). The pure fractions were collected and evaporated. The residue was converted into the hydrochloric acid salt (1:2) in $\text{C}_2\text{H}_5\text{OH}$. Yielding :
30 2.63g of 1-[2-(5,6-dihydrospiro[11*H*-imidazo[2,1-b][3]benzazepine-11,4'-piperidin]-1'-yl)ethyl]-4-ethyl-1,4-dihydro-5*H*-tetrazol-5-one dihydrochloride (56%); mp. 230°C (comp. 75).

e) A mixture of chloroacetonitrile (0.11 mol), 5,6-dihydrospiro[11*H*-imidazo[2,1-b][3]benzazepine-11,4'-piperidine] (0.1 mol) and *N,N*-diethylethanamine (0.12 mol) in
35

DMF (400ml) was stirred at room temperature for 48 hours . The mixture was poured into water and extracted with CH_2Cl_2 . The organic layer was dried (MgSO_4), filtered off and evaporated. The residue was purified on a glass filter over silica gel (eluent : $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ 96/4). The pure fractions were collected and evaporated. The residue was crystallized from CH_3CN . Yielding : 18.5g 5,6-dihydrospiro[imidazo[2,1-b][3]-benzazepine-11-[11H],4'-piperidine]-1'-acetonitrile (63%); mp. 152.6°C (comp. 76).

Example B5

Bis(1,1-dimethylethyl) dicarbonate (0.095 mol) dissolved in a small amount of CH_2Cl_2 was added dropwise to a stirring mixture of compound (6) (0.079 mol) in CH_2Cl_2 (250ml). The mixture was stirred at room temperature for the weekend, then washed with H_2O , dried, filtered and the solvent was evaporated. Toluene was added and evaporated again. The residue was stirred in DIPE. The precipitate was filtered off and the filtrate was evaporated. This fraction was purified over silica gel on a glass filter (eluent: $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ 100/0, 99/1, 98/2 and 96/4). The pure fractions were collected and the solvent was evaporated. The residue was stirred in hexane. The precipitate was filtered off and dried, yielding 15.05g of 1,1-dimethylethyl 5,6-dihydrospiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine]-1'-carboxylate (54%) (comp. 7).

Example B6

a) A mixture of tetrahydro-2-furanmethanol methanesulfonate (0.01mol), compound 6 (0.01mol) and Na_2CO_3 (0.02mol) in 4-methyl-2-pentanone (150ml) was stirred and refluxed overnight. The reaction mixture was filtered over dicalite. The filtrate was evaporated. The residue was purified by column chromatography over silica gel (eluent: $\text{CH}_2\text{Cl}_2/(\text{CH}_3\text{OH}/\text{NH}_3)$ 95/5). The pure fractions were collected and the solvent was evaporated. The residue was dissolved in 2-propanone and converted into the cyclohexane sulfamic acid salt (1:2). The precipitate was filtered off and dried. Yielding: 1.48g of 5,6-dihydro-1'-[(tetrahydro-2-furanyl)methyl]spiro[imidazo[2,1-b][3]benzazepine-11-[11H],4'-piperidine] cyclohexylsulfamate(1:2) monohydrate (20.7%); mp. 120.2°C (comp. 72).

b) A mixture of compound 6 (0.02 mol) and 2-thiophenecarboxaldehyde (0.053 mol) in methanol (300ml) was hydrogenated with Raney Nickel (2g) as a catalyst. After uptake of H_2 (1eq), the catalyst was filtered off and the filtrate was evaporated. The residue was purified by column chromatography over silica gel (eluent : $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ 95/5). The pure fractions were collected and evaporated. The residue was converted into the cyclohexanesulfamic acid salt (1:1) in 2-propanone. The precipitate was filtered off and dried. The residue was recrystallized from 2-propanol. The precipitate was filtered off and dried. Yielding : 0.72g of 5,6-dihydro-1'-(2-thienyl-

methyl)spiro[imidazo[2,1-b][3]benzazepine-11-[11H],4'-piperidine] cyclohexyl-sulfamate(1:1) (6.6%); mp. 211.1°C (comp. 73).

Example B7

5 a) A mixture of compound (9) (0.155 mol), prepared according to the procedure described in Ex. No. B2 b, and MnO₂ (300g) in chloroform (1200ml) was stirred and refluxed for 90 min. The mixture was filtered over dicalite and the filtrate was evaporated. Part of this fraction (1g) was crystallized from CH₃CN. The precipitate was filtered off and dried, yielding 0.5g of 1,1-dimethylethyl 3-formyl-5,6-dihydro-

10 b) A mixture of compound (12) (0.134 mol), NaCN (0.705 mol) and MnO₂ (233g) in methanol (2500ml) was stirred at room temperature. Acetic acid (45.5ml) was added dropwise. The mixture was stirred and refluxed for 20 hours and filtered over dicalite. The filtrate was evaporated. The residue was taken up in H₂O, CH₂Cl₂ and K₂CO₃.

15 The mixture was separated into its layers. The aqueous layer was extracted with CH₂Cl₂. The combined organic layer was dried (MgSO₄), filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH 97/3). A pure fraction was collected and the solvent was evaporated, yielding 47.7g of methyl (1,1-dimethylethyl) 5,6-dihydrospiro[11H-

20 c) A mixture of compound (13) (0.056 mol) in NaOH 1N (100ml), H₂O (250ml) and THF (250ml) was stirred at room temperature for 18 hours. The organic solvent was evaporated. The aqueous concentrate was neutralized with HCl 1N (100ml) and extracted with CH₂Cl₂. The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated. Part of this fraction (2g) was crystallized from CH₃CN.


25 The precipitate was filtered off and dried, yielding 1.16g of 1'-[(1,1-dimethylethoxy)-carbonyl]-5,6-dihydrospiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine]-3-carboxylic acid (comp. 14).

30 d) A mixture of compound (14) (0.04 mol) and *N,N*-dimethyl-4-pyridinamine (0.04 mol) in CH₂Cl₂ (300ml) was stirred until complete dissolution. *N,N*-diethylethanamine (0.05 mol) was added. Then *N'*-(ethylcarbonimidoyl)-*N,N*-dimethyl-1,3-propanediamine monohydrochloride (0.05 mol) was added portionwise. The mixture was stirred at room temperature for 30 min. *N,N*-diethylethanamine (0.06 mol) was added and then NH₄Cl (0.05 mol) was added portionwise. The mixture was stirred at room temperature overnight, poured out into H₂O and separated into its layers. The aqueous layer was extracted with CH₂Cl₂. The combined organic layer was dried (MgSO₄), filtered and the solvent was evaporated. The residue was purified by column

chromatography over silica gel (eluent: $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ 97.5/2.5). The pure fractions were collected and the solvent was evaporated. The residue was crystallized from CH_3CN . The precipitate was filtered off and dried, yielding 9.5g of 1,1-dimethylethyl 3-(aminocarbonyl)-5,6-dihydrospiro[11*H*-imidazo[2,1-*b*][3]benzazepine-11,4'-piperidine]-1'-carboxylate (60%) (comp. 16).

e) A mixture of compound (16) (0.023 mol) in $\text{HCl}/2$ -propanol (25ml) and methanol (100ml) was stirred and refluxed for 90 min and then cooled. The precipitate was filtered off and dried, yielding 8g of 5,6-dihydrospiro[11*H*-imidazo[2,1-*b*][3]-benzazepine-11,4'-piperidine]-3-carboxamide dihydrochloride (94%) (comp. 17). The precipitate can also be converted into the (E)-2-butenedioic acid salt.

f) Preparation of



compound 61


A mixture of compound (17) (0.0135 mol) and NaHCO_3 (0.0271 mol) in THF (100ml) and ethanol (50ml) was stirred and refluxed for 10 min. Methyl 2-propenoate (0.0149 mol) was added. The mixture was stirred and refluxed for 3 hours and then cooled.

The solvent was evaporated under reduced pressure. The residue was partitioned between H_2O and CH_2Cl_2 . The organic layer was separated, dried (MgSO_4), filtered and the solvent evaporated. The residue was purified by column chromatography over silica gel (eluent: $\text{CH}_2\text{Cl}_2/(\text{CH}_3\text{OH}/\text{NH}_3)$ 95/5 to 90/10). The pure fractions were collected and the solvent was evaporated. The residue was purified again by column chromatography over silica gel (eluent: $\text{CH}_2\text{Cl}_2/(\text{CH}_3\text{OH}/\text{NH}_3)$ 99/1 to 97/3). The pure fractions were collected and the solvent was evaporated. The residue was refluxed in $\text{CH}_3\text{OH}/\text{diethyl ether}$ 2:8 (precipitation resulted). The precipitate was filtered off, washed with diethyl ether and dried in vacuo at 40°C overnight. Yielding: 2.27g of compound 61.

g) *N,N*-diethylethanamine (0.0081 mol) was added at room temperature to a suspension of compound 17 (0.004 mol) in methanol (100ml). The mixture was cooled to 0°C . Oxirane was bubbled through the mixture for 45 min. The mixture was allowed to warm to room temperature and then stirred at room temperature for 30 min. The solvent was evaporated under reduced pressure. The residue was purified by column chromatography over silica gel (eluent: $\text{CH}_2\text{Cl}_2/(\text{CH}_3\text{OH}/\text{NH}_3)$ 97/3 to 95/5). The pure fractions were collected and the solvent was evaporated. The residue was crystallized from $\text{CH}_3\text{OH}/\text{CH}_2\text{Cl}_2$ 1:4. The precipitate was filtered off and dried. Yielding: 0.25g of 6,11-dihydro-1'-(2-hydroxyethyl)spiro[5*H*-imidazo[2,1-*b*][3]-benzazepine-11,4'-piperidine]-3-carboxamide (18%) (compound 62).

h) Preparation of

compound 63




N,N-diethylethanamine (0.0113 mol) was added at room temperature to a suspension of compound 17 (0.0054 mol) in methanol (100ml). After 5 min, oxirane was bubbled through the mixture at 0°C for 1 hour. The solvent was evaporated. The residue was suspended in *t*-butanol (200ml). Methyl chloroacetate (0.007 mol) and *N,N*-diethylethanamine (0.0054 mol) were added. The mixture was stirred and refluxed for 48 hours. The solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/(CH₃OH/NH₃) 98/2 to 95/5). Two fractions were collected and the solvent was evaporated. Fraction 1 was crystallized from CH₃OH/CH₃CN 1:3. The precipitate was filtered off and dried. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/(CH₃OH/NH₃) 97/3 to 95/5). The pure fractions were collected and the solvent was evaporated. Yielding: 0.46g of compound 63.

i) *N,N*-diethylethanamine (0.0271 mol) was added at room temperature to a suspension of compound 17 (0.0129 mol) and ethyl α -methylenebenzeneacetate (0.0140 mol) in DMF (100ml). The mixture was stirred at room temperature over the weekend. The solvent was evaporated. The residue was extracted with CH₂Cl₂/H₂O. The mixture was separated into its layers. The precipitate in the organic layer was filtered off. Yielding: 2.6g of ethyl 3-(aminocarbonyl)-6,11-dihydro- α -phenylspiro[5*H*-imidazo-[2,1-*b*][3]benzazepine-11,4'-piperidine]-1'-propanoate monohydrochloride (compound 64).

j) Preparation of


compound 65



A mixture of compound 17 (0.0027 mol), 1-(3-chloropropyl)-1,3-dihydro-2*H*-benzimidazol-2-one (0.003 mol), Na₂CO₃ (0.0027 mol) and KI (few crystals) in CH₃CN (100ml) was stirred and refluxed for 48 hours. The solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/(CH₃OH/NH₃) 99/1 to 95/5). Two fractions were collected and their solvents were evaporated. The desired fraction was purified again by column chromatography over

silica gel (eluent: $\text{CH}_2\text{Cl}_2/(\text{CH}_3\text{OH}/\text{NH}_3)$ 97/3 to 95/5). The pure fractions were collected and the solvent was evaporated. Yielding: 0.18g of compound 65.


k) Preparation of



compound 66

A mixture of isobutyl (2-chloroethyl)carbamate (0.008 mol), 5,6-dihydrospiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine]-3-carboxamide dihydrochloride (0.004 mol), 4-methyl-2-pentanone (50 ml), Na_2CO_3 (0.020 mol) and KI (catalytic quantity) was stirred and refluxed (oil bath: 130°C) overnight. The solvent was evaporated (vacuum, 60°C). Water was added. $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ 90/10 was added. The organic layer was separated, dried (MgSO_4), filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: $\text{CH}_2\text{Cl}_2/(\text{CH}_3\text{OH}/\text{NH}_3)$ 95/5). The desired fractions were collected and the solvent was evaporated. Yield: 1.5 g of compound 66 (85.4%).

l) Preparation of



compound 67

A mixture of compound 66 (0.00227 mol) and $\text{HCl}/2$ -propanol (3 ml) in 2-propanol (30 ml) was stirred at 80°C (oil bath). The solvent was evaporated (vacuum, 40°C). 2-Propanol was added, then evaporated (2 x). Ethanol was added, then evaporated. The residue was stirred in boiling ethanol (50 ml), then filtered off over a P4 glass filter and the product was dried under a stream of N_2 . Yield: 0.254 g (24.0%). The filtrate was stirred for 3 hours while cooling on an ice-bath. The precipitate was filtered off over a P3 glass filter and dried (vacuum, 60°C , 3 hours). Yield: 0.304 g (28.7%). The filtrate was evaporated. The residue was dried (over the weekend under N_2 flow). Total yield: 70.4% of compound 67.

m) Methyl chloroformate (0.0036 mol) was added at room temperature to a suspension of compound (17) (0.0032 mol) in CH_2Cl_2 (100ml). A mixture of *N,N*-diethylethanamine (0.0097 mol) in CH_2Cl_2 (20ml) was added dropwise. The mixture was stirred at room temperature for the weekend. The solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ 99/1 to 98/2). The pure fractions were collected and the solvent was evaporated. The residue was crystallized from CH_3CN . The precipitate was filtered off and dried. Yield: 0.68g

of 3-(aminocarbonyl)-6,11-dihydrospiro[5*H*-imidazo[2,1-*b*][3]-benzazepine-11,4'-piperidine]-1'-carboxylate (60%) (comp. 79).

n) A mixture of compound (17) (0.005 mol), KOAc (2g) and paraformaldehyd (0.5g) in methanol (100ml) was hydrogenated with palladium on charcoal 10% (0.5g) as a catalyst in the presence of a thiophene solution (1ml). After uptake of H₂ (1 equiv), the catalyst was filtered off and the filtrate was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/(CH₃OH/NH₃) 97/3). The pure fractions were collected and the solvent was evaporated. This fraction was purified again by column chromatography over silica gel (eluent: CH₂Cl₂/(CH₃OH/NH₃) 97/3 to 95/5). The pure fractions were collected and the solvent was evaporated. Yield: 0.43g of 6,11-dihydro-1'-methylspiro[5*H*-imidazo[2,1-*b*][3]benzazepine-11,4'-piperidine]-3-carboxamide monohydrate (28%) (comp. 80).

Example B8

a) A solution of compound (7) (1.63 mol) in CH₂Cl₂ (7500ml) was cooled to 0°C under N₂ flow. 1-Bromo-2,5-pyrrolidinedione (1.63 mol) was added portionwise (29g each). H₂O (3000ml) was added. The mixture was stirred overnight. The organic layer was separated, dried, filtered and the solvent was evaporated. This fraction was purified by HPLC over silica gel (eluent: CH₂Cl₂/CH₃OH 100/0, 98/2, 90/10 and 100/0). A pure fraction was collected and the solvent was evaporated, yielding 189g of 1,1-dimethylethyl 2,3-dibromo-5,6-dihydrospiro[11*H*-imidazo[2,1-*b*][3]benzazepine-11,4'-piperidine]-1'-carboxylate (27%) (comp. 48). The 3-monobromo analogue (comp. 60; Ex. No. B10a) can be prepared in a similar way.

b) A mixture of compound (48) (0.02 mol), acetic acid, palladium(2+) salt (0.15g) and 1,3-propanediylbis[diphenylphosphine] (0.55g) in THF (150ml) was stirred in an autoclave at 150°C for 16 hours under pressure of CO gas (30 bar) and NH₃ gas (10 atm). The mixture was cooled, filtered and the filtrate was evaporated. This fraction was purified over silica gel on a glass filter (eluent: CH₂Cl₂/CH₃OH 95/5). The pure fractions were collected and the solvent was evaporated. The residue was crystallized from CH₃CN. The precipitate was filtered off and dried, yielding 1,1-dimethylethyl 2,3-bis(aminocarbonyl)-5,6-dihydrospiro[11*H*-imidazo[2,1-*b*][3]benzazepine-11,4'-piperidine]-1'-carboxylate (comp. 49).

Example B9

Dibenzoyl peroxide (0.5g) was added to a stirring mixture of compound (7) (0.039 mol) in CH₂Cl₂ (210ml). 1-Chloro-2,5-pyrrolidinedione (0.078 mol) in a small amount of CH₂Cl₂ was added dropwise. The mixture was stirred at room temperature overnight. The solvent was evaporated. H₂O was added and the mixture was extracted with

CH₂Cl₂. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was purified over silica gel on a glass filter (eluent: CH₂Cl₂/CH₃OH 100/0, 99/1, 98/2, 96/4 and 94/6). The pure fractions were collected and the solvent was evaporated. Some starting material (7.5g; 0.02 mol) was recuperated. The reaction was carried out again. Dibenzoyl peroxide (0.5g) was added to a stirring mixture of compound (7) (0.02 mol) in CH₂Cl₂ (210ml). 1-Chloro-2,5-pyrrolidinedione (0.078 mol) in a small amount of CH₂Cl₂ was added dropwise. The mixture was stirred at room temperature overnight. The solvent was evaporated. H₂O was added and the mixture was extracted with CH₂Cl₂. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was purified over silica gel on a glass filter (eluent: CH₂Cl₂/CH₃OH 100/0, 99/1 and 98.5/1.5). The pure fractions were collected and the solvent was evaporated. The residue was combined with the one obtained from the first reaction, yielding 14g of 1,1-dimethylethyl 3-chloro-5,6-dihydrospiro[11*H*-imidazo[2,1-*b*][3]benzazepine-11,4'-piperidine]-1'-carboxylate (93%) (comp. 19).

Example B10

a) CH₂Cl₂ (87 ml) was added to 1,1-dimethylethyl 5,6-dihydrospiro[11*H*-imidazo[2,1-*b*][3]benzazepine-11,4'-piperidine]-1'-carboxylate (comp. 7) in methanol (0,0582 mol). Water (58 ml) was added. Water (58 ml) and Na₂CO₃ (0.0582 mol) were added to the separated organic layer and the mixture was cooled to 0-5°C (solution 1). Br₂ (0.0565 mol) was added to a solution of tetrabutylammoniumbromide (0.0565 mol) and CH₂Cl₂ (29 ml). This mixture was stirred for 25 minutes at 15-25°C and added to solution 1 during 1 hour. After stirring for 1 hour at 20°C, water (58 ml) was added. The separated organic layer was evaporated. 3-Methyl-2-butanone (87 ml) and water (29 ml) were added to the oily residue and this mixture was heated to 80°C. The separated organic layer was washed with water (29ml) at 80°C. The organic layer was azeotroped till 116°C. 3-Methyl-2-butanone (40.7 ml) was distilled off and the product was crystallized during 2 hours at 50°C. The crystallized product was filtered off, washed with 3-methyl-2-butanone and dried (vacuum, 50°C). Yield : 13.03g of 1,1-dimethylethyl 3-bromo-5,6-dihydrospiro[11*H*-imidazo[2,1-*b*][3]benzazepine-11,4'-piperidine]-1'-carboxylate (51.8%) (comp. 60).

b) A mixture of compound (60) (0.257 mol), DMF (515 ml), H₂O (26 ml) and CuCN (1,287 mol) were heated till 132°C, stirred for 17 hours and then cooled to room temperature. The mixture was poured into 2056 ml of H₂O and stirred for 2 hours. The precipitate was filtered off, washed twice with H₂O (149 ml) and dried (vacuum, 100°C). The resulting precipitate was refluxed in 3-methyl-2-butanone (772 ml) for 30

min, followed by cooling the reaction mixture to 50°C and filtering. NH₄OH (129 ml) was added to the filtrate at 50°C and stirred for 30 min. The 3-methyl-2-butanone layer was separated and washed with NH₄OH (129 ml) as described above. This procedure was repeated for another 5 times. The 3-methyl-2-butanone layer was separated again, azeotroped for 30 min and partially evaporated. The resulting mixture was crystallized and the precipitate was filtered, washed with 3-methyl-2-butanone (7.7 ml) and dried (vacuum, 50°C). Yield : 52.4 g of 1,1-dimethylethyl 3-(aminocarbonyl)-5,6-dihydro-spiro[11*H*-imidazo[2,1-*b*][3]benzazepine-11,4'-piperidine]-1'-carboxylate (53%) (comp. 16).

Example B11

a) A mixture of intermediate (18) (0.152 mol) in trifluoromethanesulfonic acid (500ml) was stirred at 158°C for 90 hours. The mixture was cooled, poured out on ice and K₂CO₃ (800g) and extracted with CH₂Cl₂. The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated partially until 100ml while the temperature was kept below 40°C. The concentrate was purified immediately by column chromatography over silica gel (eluent: CH₂Cl₂/(CH₃OH/NH₃) 95/5). The pure fractions were collected and the solvent was evaporated, yielding 18.1g of 1-methyl-spiro[11*H*-imidazo[2,1-*b*][3]benzazepine-11,4'-piperidin]-6(5*H*)-one (42%) (comp. 22). Part of this fraction (1.5g) was dissolved in ethanol and converted into the (E)-2-butenedioic acid salt (2:3). The precipitate was filtered off and dried, yielding 1.92g of 1-methylspiro[11*H*-imidazo[2,1-*b*][3]benzazepine-11,4'-piperidin]-6(5*H*)-one (E)-2-butenedioic acid salt (2:3) (comp. 22a).

b) A mixture of intermediate (24) (0.041 mol) in HBr 48% solution (250ml) was stirred and refluxed for 4 hours. The mixture was poured out on ice and K₂CO₃ and extracted with CH₂Cl₂. The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated, yielding 10.4g of spiro[11*H*-imidazo[2,1-*b*][3]benzazepine-11,4'-piperidin]-6(5*H*)-one (95%) (comp. 23). Part of this fraction (0.9g) was dissolved in ethanol and converted into the (E)-2-butenedioic acid salt (2:3). The precipitate was filtered off and dried, yielding 0.78g of spiro[11*H*-imidazo[2,1-*b*][3]benzazepine-11,4'-piperidin]-6(5*H*)-one (E)-2-butenedioic acid salt (2:3) (comp. 23a).

c) A mixture of compound (23) (0.01 mol) in methanol (300ml) was stirred on an ice bath. NaBH₄ (0.02 mol) was added portionwise over a 15-min period. The mixture was stirred on an ice bath for 1 hour. The solvent was evaporated at a temperature below 40°C. The residue was taken up in H₂O and the mixture was extracted with CH₂Cl₂/CH₃OH 90/10. The organic layer was separated, dried (MgSO₄), filtered and the

solvent was evaporated, yielding 2g of 5,6-dihydrospiro[11*H*-imidazo[2,1-*b*][3]-benzazepine-11,4'-piperidine]-6-ol (75%) (comp. 26).

- d) A mixture of compound (26) (0.0075 mol) in methanesulfonic acid (50ml) was stirred at room temperature for 40 min. The mixture was poured out on ice, alkalized with a NaOH 50% solution and extracted with CH₂Cl₂. The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated, yielding 2g of spiro[11*H*-imidazo[2,1-*b*][3]benzazepine-11,4'-piperidine] (100%) (comp.27). Part of this fraction (0.3g) was dissolved in ethanol and converted into the (E)-2-butenedioic acid salt (1:1). The precipitate was filtered off and dried, yielding 0.26g spiro[11*H*-imidazo[2,1-*b*][3]benzazepine-11,4'-piperidine] (E)-2-butenedioic acid salt (1:1) (comp. 27a).

Example B12


- A mixture of compound (24) (0.0128 mol) in H₂SO₄ (5ml) and methanol (100ml) was stirred and refluxed for the weekend. The solvent was evaporated. The residue was taken up in H₂O. The mixture was alkalized with a NaOH solution and extracted with CH₂Cl₂. The organic layer was separated, dried, filtered and the solvent was evaporated, yielding 4.4g of 5,6-dihydro-2,3-bis(methoxymethyl)spiro[11*H*-imidazo[2,1-*b*][3]benzazepine-11,4'-piperidine] (100%) (comp. 31).

Example B13

- a) A mixture of 5,6-dihydrospiro[imidazo[2,1-*b*][3]benzazepine-11-[11*H*],4'-piperidine]-1'-acetonitrile (comp. 76) (0.055 mol) in NH₃/CH₃OH (500ml) was hydrogenated with Raney Nickel (2g) as a catalyst at room temperature. After uptake of H₂ (2eq), the catalyst was filtered off and the filtrate was evaporated. Yielding : 20.9g of 5,6-dihydrospiro[imidazo[2,1-*b*][3]benzazepine-11-[11*H*],4'-piperidine]-1'-ethanamine 2-propanolate(2:1). trihydrochloride. sesquihydrate; mp. 245.9°C (comp. 77).
- b) A mixture of 2-chloropyrimidine (0.012mol), 5,6-dihydro-spiro[imidazo[2,1-*b*][3]-benzazepine-11-[11*H*],4'-piperidine]-1'-ethanamine (0.01mol) and Na₂CO₃ (0.02mol) in 4-methyl-2-pentanone (200ml) was stirred and refluxed for 48 hours. The reaction mixture was filtered over dicalite. The filtrate was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/(CH₃OH/NH₃) 95/5). The pure fractions were collected and the solvent was evaporated. The residue was dissolved in 2-propanol and converted into the hydrochloric acid salt (1:3). The precipitate was filtered off and dried. Yielding: 0.94g of 5,6-dihydro-*N*-2-pyrimidinyl-spiro[imidazo[2,1-*b*][3]benzazepine-11-[11*H*],4'-piperidine]-1'-ethanamine trihydrochloride. monohydrate.2-propanolate(1:1) (16.7%) (comp. 78).

- c) 3-Chloro-6-(3-methyl-1,2,4-thiadiazol-5-yl)pyridazine (0.01 mol) and 5,6-dihydro-spiro[imidazo[2,1-b][3]benzazepine-11-[11*H*],4'-piperidine]-1'-ethanamine (0.01 mol) were stirred at 140°C for 2h. The mixture was cooled and purified by column chromatography over silica gel (eluent : CH₂Cl₂/(CH₃OH/NH₃) 95/5). The pure fractions were collected and evaporated. The residue was converted into the hydrochloric acid salt (1:4) in 2-propanol and dried. Yielding : 2.22g of 2-[[2-(5,6-dihydro-spiro[imidazo[2,1-b][3]benzazepine-11-[11*H*],4'-piperidin]-1'-yl)ethyl]amino]-4(1*H*)-pyrimidinone trihydrochloride.2-propanolate(1:1). sesquihydrate (36.6%) (comp. 68).
- 10 The following Tables list compounds of formula (I) as prepared according to one of the above examples (Ex. No.).

Table 2




Co. No.	Ex. No.	R ₁	R ₂	L	Salt / Melting point
1	B3	H	H	CH ₃	(1); mp. 182.8°C
3	B4a	H	H	CH ₂ CH ₂ CH ₂ CH ₃	mp. 268.5°C
4	B2a	H	H	C(=O)OCH ₂ CH ₃	-
5	B2b	CH ₂ OH	H	C(=O)OCH ₂ CH ₃	-
6	B1	H	H	H	-
6a	B1	H	H	H	(2); mp. 278.5°C
7	B5	H	H	C(=O)OC(CH ₃) ₃	-
9	B2b	CH ₂ OH	H	C(=O)OC(CH ₃) ₃	-
10	B2b	CH ₂ OH	CH ₂ OH	C(=O)OC(CH ₃) ₃	-
12	B7a	C(=O)H	H	C(=O)OC(CH ₃) ₃	-
13	B7b	C(=O)OCH ₃	H	C(=O)OC(CH ₃) ₃	-
14	B7c	C(=O)OH	H	C(=O)OC(CH ₃) ₃	-
15	B7e	C(=O)OCH ₃	H	H	-
15a	B7e	C(=O)OCH ₃	H	H	(3); -
18	B2c/B7e	CH ₂ OH	H	H	-
18a	B2c	CH ₂ OH	H	H	(4); -

Co. No.	Ex. No.	R ₁	R ₂	L	Salt / Melting point
19	B9	Cl	H	C(=O)OC(CH ₃) ₃	-
20	B7e	Cl	H	H	(3); -
24	B7e	CH ₂ OH	CH ₂ OH	H	-
31	B12	CH ₂ OCH ₃	CH ₂ OCH ₃	H	-
35	B1	CH ₂ NHC(=O)CH ₃	H	H	-
39	B1	CH ₂ NHC(=O)NH ₂	H	H	-
43	B1	CH ₂ NHSO ₂ CH ₃	H	H	-
48	B8a	Br	Br	C(=O)OC(CH ₃) ₃	-
49	B8b	C(=O)NH ₂	C(=O)NH ₂	C(=O)OC(CH ₃) ₃	-
51	B7e	CH ₂ OCH ₃	CH ₂ OH	H	-
52	B7e	CH ₂ OH	CH ₂ OCH ₃	H	-
53	B7e	C(=O)NH ₂	C(=O)NH ₂	H	(2); -

(1) cyclohexylsulfamate (1:2); (2) hydrochloric acid (1:2); (3) (E)-2-butenedioate (1:1); (4) (E)-2-butenedioate (2:1)

Table 3




Co No.	Ex. No.	R ₁	-A-B-	Salt/Melting point
8	B1	H	-CH=CF-CH=CH-	(5); -
11	B1	H	-CH=CH-CH=CCH ₃ -	-
21	B1	H	-CH=C(OH)-CH=CH-	-
29	B1	H	-C(OH)=CH-CH=CH-	-
30	B1	H	-CH=CH-C(OH)=CH-	-
32	B1	H	-CH=C(OCH ₃)-C(OCH ₃)=CH-	-
32a	B1	H	-CH=C(OCH ₃)-C(OCH ₃)=CH-	(6); -
34	B1	H	-CH=C(OH)-C(OH)=CH-	-
46	B7e	CH ₂ OH	-CH=C(OCH ₃)-C(OCH ₃)=CH-	-
50	B7e	Cl	-CH=C(OCH ₃)-C(OCH ₃)=CH-	-
54	B2c	H	-CH=CH-S-	-
55	B1	H	-CH=CH-N(CH ₃)-	-

-48-

Co No.	Ex. No.	R ₁	-A-B-	Salt/Melting point
57	B2c	H	-S-CH=CH-	-
58	B12	-CH ₂ -O-CH ₃	-CH=CH-CH=CH-	-

(3) (E)-2-butenedioate (1:1); (5) hydrochloric acid (1:1); (6) (E)-2-butenedioate (2:3)


Table 4



Co. No.	Ex. No.	n	z	R ₁	L	Salt / Melting point
2	B1	2	-(CH ₂) ₂ -	H	H	(5); mp. 238.6°C
22	B11a	1	-C(=O)CH ₂ -	H	CH ₃	-
22a	B11a	1	-C(=O)CH ₂ -	H	CH ₃	(6); -
23	B11b	1	-C(=O)CH ₂ -	H	H	-
23a	B11b	1	-C(=O)CH ₂ -	H	H	(6); -
25	B1	1	-CH ₂ -	H	H	-
25a	B1	1	-CH ₂ -	H	H	(3); -
26	B11c	1	-CHOH-CH ₂ -	H	H	-
27	B11d	1	-CH=CH-	H	H	-
27a	B11d	1	-CH=CH-	H	H	(3); -
28	B1	1	-(CH ₂) ₃ -	H	H	-
33	B1	1	-O-CH ₂ -	H	H	-
33a	B1	1	-O-CH ₂ -	H	H	(3); -
36	B5	1	-(CH ₂) ₃ -	H	C(=O)OC(CH ₃) ₃	-
37	B2b	1	-(CH ₂) ₃ -	CH ₂ OH	C(=O)OC(CH ₃) ₃	-
38	B7e	1	-(CH ₂) ₃ -	CH ₂ OH	H	-
42	B1	1	-(CH ₂) ₄ -	H	H	-
59	B3	2	-(CH ₂) ₂ -	H	CH ₃	mp. 119.2°C
60	B10a	1	-(CH ₂) ₂ -	Br	-C(=O)OC(CH ₃) ₃	-

(3) (E)-2-butenedioate (1:1); (5) hydrochloric acid (1:1); (6) (E)-2-butenedioate (2:3)


Table 5












Co. No.	Ex. No.	L	Salt / Melting point
61	B7f	$-(\text{CH}_2)_2-\text{C}(=\text{O})\text{OCH}_3$	(7)
62	B7g	$-(\text{CH}_2)_2-\text{OH}$	-
63	B7h	$-\text{CH}_2-\text{C}(=\text{O})\text{OCH}_3$	-
64	B7i		(5)
65	B7j		(7)
66	B7k	$-(\text{CH}_2)_2-\text{NH}-\text{C}(=\text{O})\text{OC}(\text{CH}_3)_3$	-
67	B7l	$-(\text{CH}_2)_2-\text{NH}_2$	(8)
16	B7d/B10b	$-\text{C}(=\text{O})\text{OC}(\text{CH}_3)_3$	-
17	B7e	H	(2); mp. 275.6°C
41	B1	H	-
79	B7m	$-\text{C}(=\text{O})\text{OCH}_3$	-
80	B7n	$-\text{CH}_3$	(7); -

(2) hydrochloric acid (1:2); (5) hydrochloric acid (1:1); (7) monohydrate; (8) hydrochloric acid (1:3) monohydrate


5 Table 6



Co. No.	Ex. No.	L	Salt/Melting point
69	B4d		(9); mp. 260.4°C;
70	B4d		mp. 189.0°C
71	B4b		(1); mp. 180°C;
72	B6a		(10); mp. 120.2°C;
73	B6b		(11); mp. 211.1°C
74	B4c		(12); mp. 255.4°C
75	B4d		(2); mp. 230°C
76	B4e	-CH ₂ -CN	mp. 152.6°C
77	B13a	-(CH ₂) ₂ -NH ₂	(13); mp. 245.9°C
78	B13b		(14); mp. 216.1°C
68	B13c		(15); mp. 261.3°C

(1) cyclohexylsulfamate (1:2); (2) hydrochloric acid (1:2); (9) hydrochloric acid (1:3) hydrate (2:1) ethanolate (2:1); (10) cyclohexylsulfamate (1:2) hydrate (1:2); (11) cyclohexylsulfamate (1:1); (12) hydroiodic acid (1:1); (13) hydrochloric acid (1:3) hydrate (2:3) 2-propanolate (2:1); (14) hydrochloric acid (1:3) hydrate (1:1) 2-propanolate (1:1); (15) hydrochloric acid (1:3) hydrate (2:3) 2-propanolate (1:1)

Table 7



Co. No.	Ex. No.	z	R ₁	A-B-	L	Salt
40	B5	-(CH ₂) ₂ -	H	-CH=C(OCH ₃)-C(OCH ₃)=CH-	C(=O)OC(CH ₃) ₃	-
44	B9	-(CH ₂) ₂ -	Cl	-CH=C(OCH ₃)-C(OCH ₃)=CH-	C(=O)OC(CH ₃) ₃	-
44a	B7e	-(CH ₂) ₂ -	Cl	-CH=C(OCH ₃)-C(OCH ₃)=CH-	C(=O)OC(CH ₃) ₃	(3); -
45	B2b	-(CH ₂) ₂ -	CH ₂ OH	-CH=C(OCH ₃)-C(OCH ₃)=CH-	C(=O)OC(CH ₃) ₃	-
47	B1	-CH ₂ -	H	-CH=C(OCH ₃)-C(OCH ₃)=CH-	H	-
47a	B1	-CH ₂ -	H	-CH=C(OCH ₃)-C(OCH ₃)=CH-	H	(3); -
56	B2c	-CH=CH-	H	-CH=CH-S-	H	-
56a	B2c	-CH=CH-	H	-CH=CH-S-	H	(3)

(3) (E)-2-butenedioate (1:1)

C. Pharmacological Example

The ED₅₀ values (mg/kg) in the test "Protection of Rats from Compound 48/80 induced

5 Lethality" for the compounds of formula (I) are listed in the Table below.

Compound No.	ED ₅₀ (mg/kg)
1	2.5
3	2.5
17	0.04
18a	0.08
20	0.31
53	0.31
56a	2.5
58	2.5
62	0.63
64	0.31
79	0.04
80	0.63

D. Composition Examples

10 The following formulations exemplify typical pharmaceutical compositions suitable for systemic or topical administration to warm-blooded animals in accordance with the present invention.

"Active ingredient" (A.I.) as used throughout these examples relates to a compound of formula (I), a prodrug, an addition salt, a N-oxide, a quaternary amine or a stereochemically isomeric form thereof.

Example D1 : Oral drops

500 g of the A.I. is dissolved in 0.5 l of 2-hydroxypropanoic acid and 1.5 l of the polyethylene glycol at 60~80°C. After cooling to 30~40°C there are added 35 l of polyethylene glycol and the mixture is stirred well. Then there is added a solution of 1750 g of sodium saccharin in 2.5 l of purified water and while stirring there are added 2.5 l of cocoa flavor and polyethylene glycol q.s. to a volume of 50 l, providing an oral drop solution comprising 10 mg/ml of the A.I. The resulting solution is filled into suitable containers.

Example D2: Oral solutions

9 g of methyl 4-hydroxybenzoate and 1 g of propyl 4-hydroxybenzoate are dissolved in 4 l of boiling purified water. In 3 l of this solution are dissolved first 10 g of 2,3-dihydroxybutanedioic acid and thereafter 20 g of the A.I. The latter solution is combined with the remaining part of the former solution and 12 l of 1,2,3-propanetriol and 3 l of sorbitol 70% solution are added thereto. 40 g of sodium saccharin are dissolved in 0.5 l of water and 2 ml of raspberry and 2 ml of gooseberry essence are added. The latter solution is combined with the former, water is added q.s. to a volume of 20 l providing an oral solution comprising 5 mg of the A.I. per teaspoonful (5 ml). The resulting solution is filled in suitable containers.

Example D3 : Capsules

20 g of the A.I., 6 g sodium lauryl sulfate, 56 g starch, 56 g lactose, 0.8 g colloidal silicon dioxide, and 1.2 g magnesium stearate are vigorously stirred together. The resulting mixture is subsequently filled into 1000 suitable hardened gelatin capsules, each comprising 20 mg of the A.I..

Example D4 : Film-coated tabletsPreparation of tablet core

A mixture of 100 g of the A.I., 570 g lactose and 200 g starch is mixed well and thereafter humidified with a solution of 5 g sodium dodecyl sulfate and 10 g polyvinylpyrrolidone (Kollidon-K 90®) in about 200 ml of water. The wet powder mixture is sieved, dried and sieved again. Then there are added 100 g microcrystalline cellulose (Avicel®) and 15 g hydrogenated vegetable oil (Sterotex ®). The whole is mixed well and compressed into tablets, giving 10.000 tablets, each comprising 10 mg of the active ingredient.

Coating


To a solution of 10 g methyl cellulose (Methocel 60 HG®) in 75 ml of denaturated ethanol there is added a solution of 5 g of ethyl cellulose (Ethocel 22 cps ®) in 150 ml of dichloromethane. Then there are added 75 ml of dichloromethane and 2.5 ml

-53-

1,2,3-propanetriol. 10 g of polyethylene glycol is molten and dissolved in 75 ml of dichloromethane. The latter solution is added to the former and then there are added 2.5 g of magnesium octadecanoate, 5 g of polyvinylpyrrolidone and 30 ml of concentrated colour suspension (Opaspray K-1-2109®) and the whole is homogenated. The
5 tablet cores are coated with the thus obtained mixture in a coating apparatus.

Claims

1. A compound of formula



a prodrug, a *N*-oxide, an addition salt, a quaternary amine or a stereochemically isomeric form thereof wherein

R^1 is hydrogen, C_{1-6} alkyl, halo, formyl, carboxyl, C_{1-6} alkyloxycarbonyl, C_{1-6} alkylcarbonyl, $N(R^3R^4)C(=O)-$, $N(R^3R^4)C(=O)N(R^5)-$, ethenyl substituted with carboxyl or C_{1-6} alkyloxycarbonyl, or C_{1-6} alkyl substituted with hydroxy, carboxyl, C_{1-6} alkyloxy, C_{1-6} alkyloxycarbonyl, $N(R^3R^4)C(=O)-$, C_{1-6} alkyl $C(=O)N(R^5)-$, C_{1-6} alkyl $S(=O)_2N(R^5)-$ or $N(R^3R^4)C(=O)N(R^5)-$;

wherein each R^3 and each R^4 independently are hydrogen or C_{1-4} alkyl;

R^5 is hydrogen or hydroxy;

R^2 is hydrogen, C_{1-6} alkyl, hydroxy C_{1-6} alkyl, C_{1-6} alkyloxy C_{1-6} alkyl, $N(R^3R^4)C(=O)-$, aryl or halo;

n is 1 or 2;

-A-B- represents a bivalent radical of formula

-Y-CH=CH- (a-1);

-CH=CH-Y- (a-2); or

-CH=CH-CH=CH- (a-3);

wherein each hydrogen atom in the radicals (a-1) to (a-3) may independently be replaced by R^6 wherein R^6 is selected from C_{1-6} alkyl, halo, hydroxy, C_{1-6} alkyloxy, ethenyl substituted with carboxyl or C_{1-6} alkyloxycarbonyl, hydroxy C_{1-6} alkyl, formyl, carboxyl and hydroxycarbonyl C_{1-6} alkyl; each Y independently is a bivalent radical of formula -O-, -S- or -NR⁷-; wherein R^7 is hydrogen, C_{1-6} alkyl or C_{1-6} alkylcarbonyl;

Z is a bivalent radical of formula

-(CH₂)_p- (b-1),

-CH=CH- (b-2),

-CH₂-CHOH- (b-3),

-CH₂-O- (b-4),

-CH₂-C(=O)- (b-5), or

-CH₂-C(=NOH)- (b-6),

L is hydrogen; C₁₋₆alkyl; C₂₋₆alkenyl; C₁₋₆alkylcarbonyl; C₁₋₆alkyloxycarbonyl;

L represents a radical of formula

Alk represents C₁₋₄alkanediyl ;

Y represents O, S or NH ;

Cc1c(C)c(=O)n(c1=NC2=CC=CC=C2)Z

wherein

25 A-Z represents S-CH=CH, S-CH₂-CH₂, S-CH₂-CH₂-CH₂, CH=CH-CH=CH, or CH₂-CH₂-CH₂-CH₂;

aryl is phenyl or phenyl substituted with 1, 2 or 3 substituents each independently selected from halo, hydroxy, C₁₋₄alkyl, polyhaloC₁₋₄alkyl, cyano, aminocarbonyl, C₁₋₄alkyloxy or polyhaloC₁₋₄alkyloxy;
provided that 5,6-dihydrospiro[imidazo[1,2-b][3]benzazepine-11[11*H*],4'-piperidine] and pharmaceutically acceptable addition salts thereof are not included.


2. A compound according to claim 1 wherein L is hydrogen, C₁₋₆alkyl, C₁₋₆alkylcarbonyl, C₁₋₆alkyloxy carbonyl or C₁₋₆alkyl substituted with hydroxy, carboxyl, C₁₋₆alkyloxy or C₁₋₆alkyloxy carbonyl.

3. A compound according to claim 1 wherein L is C₁₋₆alkyl substituted with aryl and C₁₋₆alkyloxycarbonyl.
- 5 4. A compound according to any one of the preceding claims wherein -A-B- is a bivalent radical of formula -CH=CH-CH=CH- (a-3) or -CH=CH-Y- (a-2).
5. A compound according to any one of the preceding claims wherein Z is -(CH₂)_p- (b-1), -CH=CH- (b-2), or -CH₂-O- (b-4).
- 10 6. A compound according to claims 1, 2, 4 or 5 wherein L is hydrogen, C₁₋₆alkyl, hydroxyC₁₋₆alkyl, carboxyC₁₋₆alkyl, C₁₋₆alkyloxycarbonyl, or C₁₋₆alkyloxycarbonylC₁₋₆alkyl.
- 15 7. A compound according to any one of the preceding claims wherein R¹ is hydroxyC₁₋₆alkyl, formyl, C₁₋₆alkyloxycarbonyl, C₁₋₆alkyloxyC₁₋₆alkyl, N(R³R⁴)C(=O)-, halo or hydrogen.
- 20 8. A compound according to claim 1 wherein the compound is
 5,6-dihydrospiro[11*H*-imidazo[2,1-*b*][3]benzazepine-11,4'-piperidine]-3-carboxamide dihydrochloride;
 1'-butyl-5,6-dihydrospiro[imidazo[2,1-*b*] [3] benzazepine-11-[11*H*],4'-piperidine];
 6,11-dihydro-1'-methylspiro[5*H*-imidazo[2,1-*b*][3]benzazepine-11,4'-piperidine]
 cyclohexylsulfamate(1:2);
 25 6,11-dihydrospiro[5-imidazo[2,1-*b*][3]benzazepine-11,4'-piperidine]-3-methanol]
 (E)-2-butenedioate (2:1);
 3-chloro-6,11-dihydrospiro[5*H*-imidazo[2,1-*b*][3]benzazepine-11,4'-piperidine]
 (E)-2-butenedioate (1:1);
 0 6,11-dihydro-3-(methoxymethyl)spiro[5*H*-imidazo[2,1-*b*][3]benzazepine-11,4'-
 30 piperidine]. (E)-2-butenedioate (1:1);
 6,11-dihydro-1'-(2-hydroxyethyl)spiro[5*H*-imidazo[2,1-*b*][3]benzazepine-11,4'-
 piperidine]-3-carboxamide;
 6,11-dihydro-1'-methylspiro[5*H*-imidazo[2,1-*b*][3]benzazepine-11,4'-piperidine]-3-
 carboxamide monohydrate;
 35 ethyl 3-(aminocarbonyl)-6,11-dihydro- α -phenylspiro[5*H*-imidazo[2,1-*b*][3]-
 benzazepine-11,4'-piperidine]-1'-propanoate monohydrochloride;
 3-(aminocarbonyl)-6,11-dihydrospiro[5*H*-imidazo[2,1-*b*][3]-benzazepine-11,4'-
 piperidine]-1'-carboxylate;

-57-

spiro[10*H*-imidazo[1,2-*a*]thieno[3,2-*d*]azepine-10,4'-piperidine];
 6,11-dihydrospiro[5*H*-imidazo[2,1-*b*][3]benzazepine-11,4'-piperidine]-2,3-
 dicarboxamide dihydrochloride monohydrate;
 a prodrug, a *N*-oxide, an addition salt, a quaternary amine or a stereochemically
 isomeric form thereof.

9. A compound of formula




a prodrug, a *N*-oxide, an addition salt, a quaternary amine or a stereochemically
 isomeric form thereof wherein L, n, -A-B-, Z, R¹ and R² are defined as in claim 1
 for use as a medicine.

10. A pharmaceutical composition comprising a pharmaceutically acceptable carrier, and
 as active ingredient a therapeutically effective amount of a compound as described in
 any one of claims 1 to 9.

11. A process of preparing a composition as claimed in claim 10, characterized in that, a
 pharmaceutically acceptable carrier is intimately mixed with a therapeutically
 effective amount of a compound as described in any one claims 1 to 9.

12. A compound of formula




a *N*-oxide, an addition salt, a quaternary amine or a stereochemically isomeric form
 thereof wherein P is a protective group and n, -A-B-, Z, R¹ and R² are defined as in
 claim 1, provided that 6,11-dihydro-1'-(phenylmethyl)-5*H*-spiro[imidazo[1,2-*b*][3]-
 benzazepine-11,4'-piperidine] (E)-2-butenedioate(1:2) is not included.

13. A compound according to claim 12 wherein P is benzyl.


14. A process of preparing a compound as claimed in claim 1, characterized by,

a) deprotecting an intermediate of formula (II), followed optionally by derivatizing either the piperidine moiety, or the imidazole moiety, or both the piperidine moiety and the imidazole moiety




with -A-B-, Z, L, R^1 and R^2 , and n defined as in claim 1 and P being a protective group;

b) derivatizing an intermediate of formula (II) at the imidazole moiety, leading to the formation of an intermediate of formula (II-a), followed by deprotecting the piperidine moiety, and followed optionally by derivatizing the piperidine moiety



with -A-B-, Z, L, R^1 and R^2 , and n defined as in claim 1 and P being a protective group;


c) by cyclizing an intermediate of formula (III) in the presence of an appropriate acid, resulting in a compound of formula (I-a)



with -A-B-, L, R^1 and R^2 , and n defined as in claim 1;


and, if desired, converting compounds of formula (I) and (I-a) into each other following art-known transformations, and further, if desired, converting the compounds of formula (I), into a therapeutically active non-toxic acid addition salt by treatment with an acid, or into a therapeutically active non-toxic base addition salt by treatment with a base, or conversely, converting the acid addition salt form into the free base by treatment with alkali, or converting the base addition salt into the free acid by treatment with acid; and, if desired, preparing stereochemically isomeric forms or N-oxide forms thereof.

15. A process of preparing a compound as claimed in claim 12, characterized by,
- cyclizing a compound of formula (XI) with an appropriate acid, leading to a compound of formula (II-k), followed optionally by derivatizing the imidazole moiety, leading to a compound of formula (II-a-1)



with -A-B-, R¹, R², n and P defined as in claim 13, and Z₁ being a bivalent radical of formula -(CH₂)_p-, wherein p is 1,2,3 or 4.

- by reacting a tricyclic moiety of formula (XIV) with a reagent of formula (XV) under an inert atmosphere in a reaction inert solvent in the presence of a suitable base, leading to a compound of formula (II-l), followed optionally by derivatizing the imidazole moiety leading to a compound of formula (II-a-2)




with -A-B-, R¹, R², n and P defined as in claim 13, W₅ being a suitable leaving group, e.g. a halo, and Z₂ being a bivalent radical of formula -(CH₂)_p-, or -CH₂-O-, wherein p is 1,2,3 or 4.

ABSTRACT

ANTI-HISTAMINIC SPIRO COMPOUNDS

5 This invention concerns the compounds of formula



a prodrug, a *N*-oxide, an addition salt, a quaternary amine or a stereochemically isomeric form thereof wherein R^1 is hydrogen, C_{1-6} alkyl, halo, formyl, carboxyl, C_{1-6} alkyloxycarbonyl, C_{1-6} alkylcarbonyl, $N(R^3R^4)C(=O)-$, $N(R^3R^4)C(=O)N(R^5)-$, ethenyl substituted with carboxyl or C_{1-6} alkyloxycarbonyl, or C_{1-6} alkyl substituted with hydroxy, carboxyl, C_{1-6} alkyloxy, C_{1-6} alkyloxycarbonyl, $N(R^3R^4)C(=O)-$, $C_{1-6}alkylC(=O)N(R^5)-$, $C_{1-6}alkylS(=O)_2N(R^5)-$ or $N(R^3R^4)C(=O)N(R^5)-$ wherein each R^3 and each R^4 independently are hydrogen or C_{1-4} alkyl, and R^5 is hydrogen or hydroxy; R^2 is hydrogen, C_{1-6} alkyl, hydroxy C_{1-6} alkyl, C_{1-6} alkyloxy C_{1-6} alkyl, $N(R^3R^4)C(=O)-$, aryl or halo; n is 1 or 2; -A-B- represents a bivalent radical of formula -Y-CH=CH-, -CH=CH-Y-, or -CH=CH-CH=CH-, wherein each hydrogen atom may independently be replaced by R^6 wherein R^6 is C_{1-6} alkyl, halo, hydroxy, C_{1-6} alkyloxy, ethenyl substituted with carboxyl or C_{1-6} alkyloxycarbonyl, hydroxy C_{1-6} alkyl, formyl, carboxyl or hydroxycarbonyl C_{1-6} alkyl, and each Y independently is a bivalent radical of formula -O-, -S- or -NR⁷-, wherein R^7 is hydrogen, C_{1-6} alkyl or C_{1-6} alkylcarbonyl; Z is a bivalent radical of formula -(CH₂)_p-, -CH=CH-, -CH₂-CHOH-, -CH₂-O-, -CH₂-C(=O)-, or -CH₂-C(=NOH)-, provided that the bivalent radicals are connected to the nitrogen of the imidazole ring via their -CH₂- moiety; and wherein p is 1, 2, 3 or 4; L is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{1-6} alkylcarbonyl, C_{1-6} alkyloxycarbonyl, C_{1-6} alkyl substituted with hydroxy, carboxyl, C_{1-6} alkyloxy, C_{1-6} alkyloxycarbonyl, aryl, aryloxy, cyano or R⁸HN- wherein R⁸ is hydrogen, C_{1-6} alkyl, C_{1-6} alkyloxycarbonyl, or C_{1-6} alkylcarbonyl; or L represents a radical of formula -Alk-Y¹-Het¹, -Alk-NH-CO-Het² or -Alk-Het³ wherein Alk represents C_{1-4} alkanediyl; Y¹ represents O, S or NH; Het¹, Het² and Het³ each represent an optionally substituted heterocycle; for use as a medicine.

THIS PAGE BLANK (USPTO)

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 99/10176

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D471/20 A61K31/55 A61K31/438 A61P37/00 C07D495/22
C07D487/20 C07D498/20 C07D519/00 //(C07D471/20, 235:00,
223:00, 221:00), (C07D495/22, 333:00, 235:00, 223:00, 221:00),

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 97 24356 A (JANSSEN PHARMACEUTICA NV ;) 10 July 1997 (1997-07-10) cited in the application page 14, line 25 - line 29; claims 1,8 ---	1,10
A	EP 0 518 434 A (JANSSEN PHARMACEUTICA NV) 16 December 1992 (1992-12-16) page 27, line 7 - line 13; claims 1,7 ---	1,10
A	EP 0 393 738 A (JANSSEN PHARMACEUTICA NV) 24 October 1990 (1990-10-24) page 15, line 15 - line 23; claim 1 -----	1,10

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

30 March 2000

Date of mailing of the international search report

17/04/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Alfaro Faus, I

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/10176

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 (C07D495/22, 235:00, 223:00, 221:00, 209:00), (C07D487/20, 235:00, 223:00, 223:00), (C07D471/20, 235:00, 221:00, 221:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

30 March 2000

Date of mailing of the international search report

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Alfaro Faus, I

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inte: .onal Application No

PCT/EP 99/10176

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9724356	A	10-07-1997	AU 716071 B	17-02-2000
			AU 1308697 A	28-07-1997
			BR 9612307 A	13-07-1999
			CA 2238817 A	10-07-1997
			CZ 9801865 A	11-11-1998
			EP 0843679 A	27-05-1998
			NO 982405 A	19-08-1998
			NZ 325845 A	29-06-1999
			PL 327136 A	23-11-1998
			SK 83098 A	11-01-1999
EP 0518434	A	16-12-1992	AU 652841 B	08-09-1994
			AU 1901192 A	12-01-1993
			CA 2102889 A	14-12-1992
			CN 1068116 A,B	20-01-1993
			WO 9222553 A	23-12-1992
			EP 0588859 A	30-03-1994
			FI 935557 A	10-12-1993
			HR 920156 A	31-12-1995
			HU 70428 A	30-10-1995
			IL 101851 A	14-05-1996
			JP 6507890 T	08-09-1994
			MX 9202860 A	01-12-1992
			NO 934493 A	04-01-1994
			NZ 242775 A	28-03-1995
			PL 170376 B	31-12-1996
			US 5461050 A	24-10-1995
			ZA 9204327 A	13-12-1993
			ZM 2892 A	25-05-1994
EP 0393738	A	24-10-1990	AT 114653 T	15-12-1994
			AU 615612 B	03-10-1991
			AU 5295190 A	11-10-1990
			CA 2013892 A	07-10-1990
			CN 1046161 A,B	17-10-1990
			DE 69014385 D	12-01-1995
			DE 69014385 T	20-04-1995
			DK 393738 T	16-01-1995
			ES 2067645 T	01-04-1995
			FI 95702 B	30-11-1995
			GR 3015154 T	31-05-1995
			HU 58324 A	28-02-1992
			IE 65460 B	01-11-1995
			IL 94008 A	18-02-1997
			JP 2290874 A	30-11-1990
			NO 174851 B	11-04-1994
			NZ 233088 A	25-10-1991
			PT 93671 A,B	20-11-1990
			RU 2030415 C	10-03-1995
			US 5272150 A	21-12-1993
			ZA 9002664 A	24-12-1991

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)